



EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

G. Roberts^{1,2,3*} | O. Pfaar^{4,5*} | C. A. Akdis^{6,7} | I. J. Ansotegui⁸ | S. R. Durham⁹ | R. Gerth van Wijk¹⁰ | S. Halken¹¹ | D. Larenas-Linnemann¹² | R. Pawankar¹³ | C. Pitsios¹⁴ | A. Sheikh¹⁵ | M. Worm¹⁶ | S. Arasi^{17,18} | M. A. Calderon⁹ | C. Cingi¹⁹ | S. Dhimi²⁰ | J. L. Fauquert²¹ | E. Hamelmann²² | P. Hellings^{23,24} | L. Jacobsen²⁵ | E. F. Knol²⁶ | S. Y. Lin²⁷ | P. Maggina²⁸ | R. Mösges²⁹ | J. N. G. Oude Elberink^{30,31} | G. B. Pajno¹⁷ | E. A. Pastorello³² | M. Penagos⁹ | G. Rotiroti³³ | C. B. Schmidt-Weber³⁴ | F. Timmermans³⁵ | O. Tsilochristou³⁶ | E.-M. Varga³⁷ | J. N. Wilkinson³⁸ | A. Williams³⁹ | L. Zhang⁴⁰ | I. Agache⁴¹ | E. Angier⁴² | M. Fernandez-Rivas⁴³ | M. Jutel^{44,45} | S. Lau⁴⁶ | R. van Ree⁴⁷ | D. Ryan⁴⁸ | G. J. Sturm^{49,50} | A. Muraro⁵¹

¹The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport, Isle of Wight, UK

²NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK

³Clinical and Experimental Sciences and Human Development in Health Academic Units, Faculty of Medicine, University of Southampton, Southampton, UK

⁴Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

⁵Center for Rhinology and Allergology, Wiesbaden, Germany

⁶Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland

⁷Christine Kühne Center for Allergy Research and Education, Davos, Switzerland

⁸Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Erandio, Bilbao, Spain

⁹Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK

¹⁰Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

¹¹Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark

¹²Center of Excellence in Asthma and Allergy, Hospital Médica Sur, Mexico City, Mexico

¹³Department of Pediatrics, Nippon Medical School, Tokyo, Japan

¹⁴Medical School, University of Cyprus, Nicosia, Cyprus

¹⁵Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK

¹⁶Department of Dermatology and Allergy, Charité Campus Mitte, Universitätsmedizin Berlin, Berlin, Germany

¹⁷Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy

¹⁸Molecular Allergology and Immunomodulation – Department of Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany

¹⁹Department of Otorhinolaryngology, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey

²⁰Evidence Based Health Care Ltd, Edinburgh, UK

²¹CHU Clermont-Ferrand University Hospital (CHU Estaing), Unité d'allergologie de l'enfant, Clermont-Ferrand, France

²²Children's Hospital Bethel, EvKB, Bielefeld University, Bielefeld, Germany

²³Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium

Abbreviations: AGREE II, Appraisal of Guidelines for Research & Evaluation; AIT, allergen immunotherapy; AR, allergic rhinoconjunctivitis; ARIA, Allergic Rhinitis and its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; EMA, European Medicines Agency; EPIT, epicutaneous immunotherapy; HDM, house dust mite; ICER, incremental cost-effectiveness ratio; NARES, nonallergic rhinitis with eosinophilia syndrome; QALY, quality-adjusted life years; RCT, randomized controlled trial; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; SMD, standardized mean difference; SmPC, summary or product characteristics; SPT, skin prick test.

*Denotes equal contribution.

- ²⁴Department of Otorhinolaryngology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
- ²⁵Allergy Learning and Consulting, Copenhagen, Denmark
- ²⁶Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
- ²⁷Johns Hopkins Department of Otolaryngology – Head and Neck Surgery, Baltimore, MD, USA
- ²⁸Allergy and Clinical Immunology Unit, 2nd Department of Pediatrics, NKUA Athens University, Athens, Greece
- ²⁹Clinical Research International Ltd, Hamburg, Germany
- ³⁰Department of Allergology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- ³¹GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- ³²Department of Allergy and Immunology, Asst Grande Ospedale Metropolitano Niguarda, University of Milano, Milano, Italy
- ³³Department of Allergy and Medical Rhinology, The Royal National Throat Nose and Ear Hospital, University College Hospital, London, UK
- ³⁴Center of Allergy and Environment (ZAUM) & Institute of Allergy Research, Helmholtz Center Munich, Munich, Germany
- ³⁵European Anaphylaxis Taskforce – Nederlands Anafylaxis Netwerk, Dordrecht, The Netherlands
- ³⁶Division of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, Children's Allergy Service, King's College London, Guy's and St. Thomas' National Health Service Foundation Trust, London, UK
- ³⁷Department of Paediatric and Adolescent Medicine, Respiratory and Allergic Disease Division, Medical University of Graz, Graz, Austria
- ³⁸Pharmaceutical Group of the European Union, Brussels, Belgium
- ³⁹Allergy Department, Guys and St Thomas' NHS Foundation Trust, London, UK
- ⁴⁰Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
- ⁴¹Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University Brasov, Brasov, Romania
- ⁴²Department of Clinical Immunology and Allergy, Northern General Hospital, Sheffield, UK
- ⁴³Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain
- ⁴⁴ALL-MED Medical Research Institute, Wroclaw, Poland
- ⁴⁵Wroclaw Medical University, Wroclaw, Poland
- ⁴⁶Department of Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany
- ⁴⁷Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- ⁴⁸Usher Institute of Population Health Sciences and Informatics, University of Edinburgh Medical School, Edinburgh, UK
- ⁴⁹Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria
- ⁵⁰Outpatient Allergy Clinic Reumannplatz, Vienna, Austria
- ⁵¹Department of Women and Child Health, Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, University of Padua, Padua, Italy

Correspondence

Antonella Muraro, Department of Women and Child Health, Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, University of Padua, Padua, Italy. Email: muraro@centroallergiealimentari.eu

Funding information

European Academy of Allergy & Clinical Immunology; BM4SIT project, Grant/Award Number: 601763

This Guideline published by the European Academy of Allergy and Clinical Immunology (EAACI) has drawn on data from a systematic review of the literature, more recent published studies and multi-stakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare.

Abstract

Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass

tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children.

KEYWORDS

allergen immunotherapy, allergic conjunctivitis, allergic rhinitis, allergy, rhinoconjunctivitis

1 | INTRODUCTION

Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes, resulting in a chronic, mostly eosinophilic, inflammation of the nasal mucosa and conjunctiva.^{1,2} Allergic rhinitis, with or without conjunctivitis, is one of the most prevalent allergic diseases affecting around a fifth of the general population.³⁻⁵ It is associated with considerable loss of productivity and impaired school performance.⁶


Allergic rhinoconjunctivitis can usually be diagnosed from its typical presentation (Figure 1). Symptoms include itching, sneezing, watery nasal discharge, and nasal congestion.² Commonly, there are associated ocular symptoms (watery, red and/or itchy eyes). Symptoms may be described as seasonal and/or perennial; as intermittent or persistent; or mild, moderate or severe according to their impact on the quality of life.⁸ Symptoms are related to exposure to the offending allergen as well as to nonspecific triggers such as smoke, dust, viral infections, strong odors, and cold air.² Symptoms on exposure to 1 or more aeroallergens supported by evidence of allergen-specific IgE sensitization to the relevant allergens confirm the diagnosis. AR may co-exist with other forms of rhinitis (Figure 1).

Additionally, AR may be associated with symptoms of sinusitis, hearing problems, and asthma.²

The aims of AR management are to control symptoms and reduce inflammation. Where possible, allergen avoidance can be recommended. Effective allergen avoidance is, however, often not feasible.^{9,10} Many patients rely on pharmacotherapy with, for example, oral or topical antihistamines, intranasal corticosteroids, topical cromoglycate, or leukotriene receptor antagonists.² However, these therapies do not alter the natural history of AR and may also induce side-effects. Additionally, despite medication, a significant number of patients continue to experience symptoms that impair their quality of life. Allergen immunotherapy (AIT) with the subcutaneous (SCIT) or sublingual (SLIT) administration of the culprit allergen(s) may not only desensitize a patient, thereby ameliorating symptoms, but also deliver long-term clinical benefits that may persist for years after discontinuation of treatment.¹¹⁻¹³

This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Guideline on Allergen Immunotherapy: Allergic Rhinoconjunctivitis Taskforce and is part of the EAACI Guidelines on Allergen Immunotherapy. This Guideline aims to provide evidence-based recommendations for the use of AIT

FIGURE 1 Differential diagnosis of allergic rhinoconjunctivitis. Adapted from Roberts *et al* 2013.⁷ Local allergic rhinitis may be seen where there is only evidence of local nasal allergic sensitization.^{15,16,26} There are numerous other causes of nonallergic, noninfectious rhinitis, an example is nonallergic rhinitis with eosinophilia syndrome (NARES). In individual patients, symptoms may be driven by more than one trigger. Rhinosinusitis is not included in the scope of this Guideline



BOX 1 Key terms

Allergen immunotherapy (AIT)	Repeated allergen administration at regular intervals to modulate immune response in order to reduce symptoms and the need of medication for clinical allergies and to prevent the development of new allergies and asthma. This is also sometimes known as allergen-specific immunotherapy, desensitization, hyposensitization, or allergy vaccination.
Conjunctivitis	Inflammation of the conjunctiva characterized by watery, itchy, red eyes.
Efficacy	<i>Short-term treatment efficacy:</i> clinical benefit to the patient while they are receiving AIT. <i>Long-term treatment efficacy:</i> clinical benefit to the patient for at least 1 y after cessation of the AIT course. ¹⁴
Rhinitis	Inflammation of the nasal mucosa resulting in at least 2 nasal symptoms: rhinorrhea, blockage, sneezing, or itching.
Sensitization	Detectable allergen-specific IgE antibodies, either by means of skin prick test (SPT) and/or specific-IgE antibodies in a serum sample.
Subcutaneous immunotherapy (SCIT)	Form of AIT where the allergen is administered as subcutaneous injections.
Sublingual immunotherapy (SLIT)	Form of AIT where the allergen is administered under the tongue with formulation as drops or fast-dissolving tablets which are administered through the sublingual route.

for patients of all ages with allergic rhinitis with or without conjunctivitis. The term AR will henceforth be used to denote either allergic rhinitis or Allergic rhinoconjunctivitis (see Box 1 for definitions of key terms). The primary audience are clinical allergists (specialist and subspecialists); the document may also provide guidance to other healthcare professionals (e.g. physicians from other disciplines, nurses, and pharmacists working across a range of primary, secondary, and tertiary care settings) dealing with AR. The development of the Guideline has been informed by a formal systematic review (SR) and meta-analysis of AIT for AR,¹⁴ with systematic review principles being used to identify additional evidence, where necessary.

2 | METHODOLOGY

This Guideline was produced using the Appraisal of Guidelines for Research & Evaluation (AGREE II) approach,^{17,18} a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a

careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated.

2.1 | Clarifying the scope and purpose of the guidelines

The scope of this EAACI Guideline is multifaceted, providing statements that assist clinicians in the optimal use of AIT in the management of patients with AR and identifying gaps for further research.

2.2 | Ensuring appropriate stakeholder involvement

Members of the EAACI Taskforce on AIT for AR represented a range of 18 countries and disciplinary and clinical backgrounds, including allergists (specialist and subspecialists), pediatricians, primary care specialists, ophthalmologists, otolaryngologists, pharmacists, immunologists, nurses, and patient representatives. Methodologists took the lead in undertaking the underpinning SR, while clinical academics took the lead in formulating recommendations for clinical care. Representatives of immunotherapy product manufacturers were given the opportunity to review and comment on the draft guidelines as part of the peer review and public comment process at the final stage. These comments were considered by Taskforce members, and, where appropriate, revisions were made.

2.3 | Systematic reviews of the evidence

The initial full range of clinical questions that were considered important was rationalized through several rounds of iteration to agree on 1 key question: What are the effectiveness, cost-effectiveness, and safety of AIT in patients with AR? This was then pursued through a formal SR of the evidence by independent methodologists as previously published^{14,19}; only double-blind RCTs were included in the effectiveness analyses. We continued to track evidence published after our SR cutoff date of October 31, 2015, and, where relevant, studies were considered by the Taskforce chairs. This evidence will formally be considered in the systematic review update that will precede the update of this Guideline (discussed below).

2.4 | Formulating recommendations

We graded the strength and consistency of key findings from the SR and performed meta-analyses, using a random-effects model to take into account the heterogeneity of findings.¹⁴ These were used to formulate evidence-based recommendations for clinical care²⁰ (Box 2). This involved formulating clear recommendations with the strength of evidence underpinning each recommendation. Where the

BOX 2 Assigning levels of evidence and strength of recommendations

Level of evidence

Level I	Systematic reviews, meta-analysis, randomized controlled trials
Level II	Two groups, non-randomized studies (e.g., cohort, case-control)
Level III	One group, non-randomized (e.g., before and after, pretest, and post-test)
Level IV	Descriptive studies that include analysis of outcomes (single-subject design, case series)
Level V	Case reports and expert opinion that include narrative literature, reviews, and consensus statements

Grades of recommendation

Grade A	Consistent level I studies
Grade B	Consistent level II or III studies or extrapolations from level I studies
Grade C	Level IV studies or extrapolations from level II or III studies
Grade D	Level V evidence or troublingly inconsistent or inconclusive studies at any level

Strength of recommendations

Strong	Evidence from studies at low risk of bias
Moderate	Evidence from studies at moderate risk of bias
Weak	Evidence from studies at high risk of bias

Recommendations are phrased according to the strength of recommendation: strong: "is recommended"; moderate: "can be recommended"; weak: "may be recommended in specific circumstances"; negative: "cannot be recommended".

Approach adapted from Oxford Centre for Evidence-based Medicine—Levels of Evidence and Grades of Recommendations.²⁰ The adaptation involved providing an assessment of the risk of bias, based on the Cochrane risk of bias tool, of the underpinning evidence and highlighting other potentially relevant contextual information.

systematic review did not cover the clinical area, we took a hierarchical approach reviewing other evidence until we could formulate a recommendation, that is: (i) other systematic reviews on the subject to see whether these provided any clarity on the topic; (ii) RCTs within these systematic reviews; (iii) other RCTs known to Taskforce members; and (iv) a consensus-based approach within the Taskforce. This evidence was graded as described in Box 2 using the SR results¹⁴ and clearly labeled in the recommendation tables. Recommendations apply to all ages unless otherwise indicated in the tables. When there were insufficient pediatric data, we extrapolated from the adult recommendation where it was biologically likely that the intervention would also be effective in children, but downgraded the recommendation by at least 1 level. Taskforce members identified the resource implications of implementing the recommendations,

barriers, and facilitators to the implementation of each recommendation, advised on approaches to implementing the recommendations, and suggested audit criteria that can help with assessing organizational compliance with each recommendation.

2.5 | Peer review and public comment

A draft of these guidelines was externally peer-reviewed by invited experts from a range of organizations, countries, and professional backgrounds. Additionally, the draft guideline was made available on public domain on the EAACI Web site for a 3-week period in May 2017 to allow a broader array of stakeholders to comment. All feedback was considered by the Taskforce members and, where appropriate, final revisions were made in light of the feedback received. We will be pleased to continue to receive feedback on this guideline, which should be addressed to the corresponding author.

2.6 | Identification of evidence gaps

The process of developing this Guideline has identified a number of evidence gaps which are prioritized (Table 10).

2.7 | Editorial independence and managing conflict of interests

This Guideline was funded and supported by EAACI. The funder did not have any influence on the guideline production process, on its contents or on the decision to publish. Taskforce members' conflicts of interest were declared at the start of the process and taken into account by the taskforce chairs as recommendations were formulated. Final decisions about strength of evidence for recommendations were checked by the methodologists who had no conflict of interests in this area.

2.8 | Updating the guidelines

European Academy of Allergy and Clinical Immunology plans to update this guideline in 2022 unless there are important advances before then.

3 | GENERAL CONSIDERATIONS BEFORE INITIATING AIT FOR AR

3.1 | General considerations

Allergen immunotherapy is only indicated in the presence of symptoms strongly suggestive of AR, with or without conjunctivitis (Table 1).^{8,14,21} Many patients will also have co-existing asthma. There should be symptoms on aeroallergen exposure with evidence of allergen-specific IgE sensitization (positive SPT or serum-specific IgE).¹⁴ Identification of the allergen(s) driving symptoms is the first level of patient stratification ensuring that the correct allergen solution is used for AIT. Occasionally, SPT or specific IgE results may

TABLE 1 General considerations for allergen immunotherapy (AIT) for allergic rhinoconjunctivitis

General indications	Key references	Contextual considerations
<p>AIT should be considered when all of these criteria are met:</p> <ul style="list-style-type: none"> • Symptoms strongly suggestive of AR, with or without conjunctivitis • There is evidence of IgE sensitization (positive SPT and/or serum-specific IgE) to one or more clinically relevant allergen • Experience moderate-to-severe symptoms which interfere with usual daily activities or sleep despite regular and appropriate pharmacotherapy and/or avoidance strategies 	Dhimi ¹⁴	A diagnosis of AR and evidence of IgE sensitization were entry criteria for RCTs in the systematic review.
AIT may also be considered in less severe AR where a patient wishes to take advantage of its long-term effect on AR and potential to prevent asthma with grass pollen AIT	Kristiansen ²⁵ Halcken ²³	AIT has the potential to alter the natural history of disease reducing AR symptoms after completing an adequate period of immunotherapy and preventing the development of asthma in the short term, up to 2 y post-AIT.
Standardized AIT products with evidence of efficacy in the clinical documentation should be used	Dhimi ¹⁴	These products have consistent formulations, and so different batches are likely to have similar effects. The meta-analysis ¹⁴ reveals a considerable heterogeneity in effectiveness between products, and therefore, a product-specific evaluation of efficacy is recommended.

The Summary of Product Characteristics (SmPC) should be checked for licensed indications which may differ between preparations.

not clearly identify the key allergen(s) causing the AR symptoms in polysensitized patients. Component resolved diagnostics may have a role in deciding which aeroallergen(s) should be chosen but definitive trials are awaited. An alternative approach is to use nasal or conjunctival provocation testing to prove the clinical relevance of the allergic sensitization in the relevant (target) organs before initiation of AIT but again definitive evidence is awaited.

Allergen immunotherapy is indicated in those patients with moderate-to-severe symptoms (e.g. Allergic Rhinitis and its Impact on Asthma (ARIA) categories moderate-to-severe intermittent or persistent²²), despite avoidance measures and pharmacotherapy, that interfere with their usual daily activities or sleep. AIT may also be considered in cases with less severe AR where the patient wishes to have the benefit of its long-term effect on rhinitis and a potential disease-modifying effect to prevent asthma.²³ AIT products with evidence of efficacy for AR should be used when available.^{11,24}

3.2 | Absolute and relative contraindications

Even when AIT is suitable for a patient with AR, clinicians must consider whether there are any specific patient-related absolute or relative contraindications (Table 2), where the risk from AIT may outweigh the expected benefits. The summary of product characteristics (SmPC) should be reviewed for specific contraindications for individual preparations.

4 | AIT FOR AR: EVIDENCE-BASED, CLINICAL RECOMMENDATIONS

To underpin this guideline, a SR of the AIT literature was undertaken.¹⁴ In general, the meta-analysis suggested that both SCIT and SLIT are effective for AR. They were associated with reductions in

symptoms and with medication use. There were insufficient data to determine which of SCIT and SLIT are most effective.

Moderate to substantial heterogeneity was observed in some outcomes evaluated in the meta-analysis.¹⁴ This heterogeneity can be explained by the study design (particularly the different outcomes used), study population and the products evaluated. There are data to indicate which preparations are most likely to be effective, so an individual product-based evaluation of the evidence for efficacy is strongly recommended before treatment with a specific product is initiated. Not all AIT products provide sufficient data to support their efficacy in clinical practice.¹⁴ As a result of this, the recent German, Austrian and Swiss guideline has followed a product-specific approach.¹¹ This approach is more difficult across Europe with differing local regulations⁴⁷ and availability of products.⁴⁸ The specific recommendations in this guideline need to be seen in this context; only standardized AIT products with evidence of efficacy in the clinical documentation should be prescribed. The only exception should be orphan allergens where only a few patients are affected; these are discussed below in the specific allergen section.

Subcutaneous immunotherapy is in general recommended for the treatment of AR in children and adults with moderate-to-severe disease that is suboptimally controlled despite pharmacotherapy¹⁴ (Table 3). The evidence for short-term benefit for continuous SCIT is stronger for seasonal rhinitis (Grade A for adults) than for perennial rhinitis (Grade B for adults), where fewer studies have been performed and results are more heterogeneous (Table 3). SCIT is recommended for seasonal disease whether pre- or pre/coseasonally (Table 3, Grade A for adults). Pre/coseasonal therapy benefits from a shorter course of treatment but the 1 head-to-head trial suggests that continuous therapy may be more effective.⁴⁹

Subcutaneous immunotherapy may be administered in aqueous formulation (rarely in Europe) or as a depot adsorbed on aluminum hydroxide or tyrosine. SCIT using either unmodified or modified

TABLE 2 General contraindications for allergen immunotherapy (AIT) for allergic rhinoconjunctivitis

	Key references	Contextual considerations
The following are considered to be contraindications:		
Uncontrolled or severe asthma	Bernstein ³¹ , Bousquet ²⁹ , Calderon ³⁴ , Cox ²⁸ , CSM 1986 ³² , Lockey ³⁰ , Normansell ³³ , Pfaar ¹¹ ; Pitsios ²⁷	Weak evidence of risk with uncontrolled asthma, active systemic autoimmune disease, and malignancy from case reports or case series of adverse events with AIT. Taskforce considered that these were contraindications to AIT.
Active, systemic autoimmune disorders (unresponsive to treatment)	Cabrera ³⁵ , Fiorillo ³⁷ , Pfaar ¹¹ , Sánchez-Morillas ³⁶ ; Pitsios ²⁷	Though initiation of AIT is contraindicated during pregnancy, an ongoing AIT is permissible when having been well tolerated by the patient in the past
Active malignant neoplasia	Larenas-Linnemann ³⁹ , Pfaar ¹¹ ; Wöhrl ³⁸	
AIT initiation during pregnancy	Metzger ⁴⁰ , Pfaar ¹¹	
With the following, AIT should only be used with caution when benefits outweigh potential risks in an individual patient:		
Partially controlled asthma	Virchow ⁴¹	One trial with SLIT tablet ⁴¹ included some subjects with partially controlled asthma without compromising safety; it is important that confirmatory evidence is acquired.
Beta-blocker therapy (local or systemic)	Cleaveland ⁴⁴ , Hiatt ⁴² , Lang ⁴⁵ ; Pfaar ¹¹	Weak evidence of risk. May compromise a patient's ability to tolerate an episode of anaphylaxis. This must be considered when deciding whether AIT is appropriate.
Severe cardiovascular diseases, for example, coronary artery disease	Larenas-Linnemann ³⁹ ; Linneberg ⁴⁶	
Systemic autoimmune disorders in remission or organ specific	Larenas-Linnemann ³⁹ , Pitsios ²⁷	Weak evidence of risk from case reports, case series of adverse events with AIT or expert opinion based on clinical experience.
Severe psychiatric disorders	Pitsios ²⁷	Taskforce considered that careful consideration on a case-by-case basis with discussion between patient and the treating physician is required before deciding whether or not to commence AIT.
Poor adherence	Pitsios ²⁷ ; Pfaar ¹¹	
Primary and secondary Immunodeficiencies	Larenas-Linnemann ³⁹ ; Pitsios ²⁷	
History of serious systemic reactions to AIT	Calderon ³⁴ ; Pfaar 2014 ¹¹	

The Summary of Product Characteristics (SmPC) should also be checked for product-specific contraindications which may differ between preparations.

allergen extracts is recommended for treatment of AR and provides short-term benefit (Table 3, Grade A for adults). This is based on evidence from the meta-analysis¹⁴ that showed both unmodified allergen extracts (SMD [95% CI] -0.65 [-0.93 , -0.36]) and allergoids/polymerized extracts (-0.60 [-0.89 , -0.31]) to be effective in reducing symptoms compared to placebo, with additional support from reduced medication requirements and combined symptom-medication scores. Although clinical trials of modified allergens involved shorter courses of treatment, there have been no head-to-head comparisons with unmodified preparations evaluating efficacy or adverse events using a placebo-controlled, randomized design.

In general, SLIT can be recommended for the treatment of seasonal AR in adults and children. SLIT has been shown to provide short-term benefit during therapy with moderate-to-severe disease that is suboptimally controlled despite pharmacotherapy (Table 3).¹⁴ SLIT is recommended to be taken either continuously or pre-/coseasonally commencing a minimum of 2 months and ideally 4 months prior to the start of the pollen season (Grade A for adults).

Sublingual immunotherapy may be taken daily either as fast tablets or drops that are retained under the tongue for at least 1 minute and then swallowed (the summary of the SmPC should also be checked for product specific recommendations). Both are recommended (grades A and B, respectively, for adults) based on short-

term reductions in symptoms and rescue medication for sublingual tablets for seasonal AR (Table 3). There are only convincing evidence for effectiveness of SLIT tablets in perennial AR (Grade A) (Table 3).

Sublingual grass pollen tablet immunotherapy for at least 3 years is recommended (Grade A) for the short-term treatment of grass pollen-driven AR in adults.^{86,87,108,109} Sublingual house dust mite (HDM) tablet immunotherapy for at least 1 year is recommended (Grade A) for the short-term treatment of perennial HDM AR in adults.⁵⁰⁻⁵⁵

While higher doses and/or increased cumulative doses may be more effective, they may be associated with more side-effects⁵⁶⁻⁵⁸; decisions on dose in AIT must be made balancing efficacy and side-effects.⁵⁹

4.1 | Other approaches of AIT for AR

Other approaches aim to improve patient convenience and adherence with shorter courses, while improving or maintaining efficacy and reducing the risk of systemic side-effects (Table 4). As such, adjuvants to AIT extracts are possible candidates.¹¹² For example, TLR-4 agonists (Th1-inducing adjuvant monophosphoryl lipid A) in combination with a grass allergoid have demonstrated effectiveness,¹¹³ although in a phase 3 trial, efficacy was modest¹¹⁴ (Grade A

TABLE 3 Recommendations: allergen immunotherapy (AIT) for treatment of allergic rhinoconjunctivitis: schedules, products, formulations

Recommendation	Children and adolescents				Other considerations	Key references
	Adults		Children and adolescents			
	Evidence level	Grade of recommendation	Evidence level	Grade of recommendation		
SCIT						
Seasonal allergic rhinitis						
Continuous SCIT is recommended for seasonal AR for short-term benefit in those with moderate-to severe disease	I	A	I	B	Consistent results, low risk of severe systemic allergic side-effects. Most studies reported pediatric and adult data together.	Dhami ¹⁴ for example, Adult: Dolz, ⁶⁴ Charpin ⁶¹ , Ferrer ⁶² , Jutel ⁷⁵ , Scadding ⁶⁵ , Walker ⁶⁰ Paediatric: Jacobsen ⁶³
Pre- and pre-/coseasonal SCIT is recommended for seasonal AR for short-term benefit	I	A	I	B	Strong recommendation for adults based on low risk of bias studies. ⁶⁹⁻⁷² Moderate recommendation for children as just one open RCT with risk of bias reporting solely pediatric data. ⁶³	Dhami ¹⁴ SR, for example, Adult: Balda, ⁶⁹ Bodtger ⁷⁰ , Bousquet ⁷⁴ , Frew, ⁵⁸ Varney ⁷¹ , Zenner ⁷² Adult/pediatric: Bousquet ⁷⁴ , Weyer ⁷³
Continuous grass pollen SCIT is recommended for seasonal AR for short- and long-term benefit	I	A	I	B	Strong recommendation for adults based on above evidence plus 2 low risk of bias long-term studies. ^{83,84} Moderate recommendation for children as one long-term open RCT with risk of bias. ⁶³	Dhami ¹⁴ SR, for example, Adult: Durham ⁸³ , James ⁸⁴ Paediatric: Jacobsen ⁶³
Perennial allergic rhinitis						
Continuous SCIT is recommended for perennial AR due to HDM for short-term benefit	I	B	I	C*	Few small adult studies, considerable heterogeneity ⁶⁶ and risk of systemic allergic side-effects. *Recommendation for children downgraded from B to C due to lack of exclusive pediatric data.	Dhami ¹⁴ SR, for example, Adult: Dokic ⁶⁷ , Ewan ⁶⁸ , Varney ⁶⁶
All						

(Continues)

TABLE 3 (Continued)

For each recommendation, an individual product-based evaluation of the evidence for efficacy is recommended before treatment with a specific product is initiated given the heterogeneity in the meta-analysis results. The SmPC should also be checked for product specific recommendations.

Recommendation	Adults		Children and adolescents		Strength of recommendation	Other considerations	Key references
	Evidence level	Grade of recommendation	Evidence level	Grade of recommendation			
Modified (allergoids) and unmodified allergen extracts for pollens and HDM SCIT are recommended for AR for short-term benefit	I	A	I	B	Strong recommendation for adults based on high-quality studies for both modified ^{61,67,76-78} and nonmodified ^{60,61,69-73,76,79,80} allergen extracts. Weak recommendation for children as no exclusive pediatric randomized, placebo-controlled data.	Consistent results, low risk of severe systemic allergic side-effects. No exclusive pediatric randomized, placebo-controlled data.	Dhami ¹⁴ SR, for example, Modified: Ceuppens ⁸¹ , Corrigan ⁷⁷ , Dokic ⁶⁷ , Klimek ⁷⁸ , Riechelmann ⁸² Nonmodified: Balda ⁶⁹ , Bodtger ⁷⁰ , Brunet ⁷⁶ , Charpin ⁶¹ , Frew ⁵⁸ , Ortolani ⁷⁹ , Scadding ⁶⁵ , Varney ⁷¹ , Walker ⁶⁰ , Weyer ⁷³ , Zenner ⁷² Modified and nonmodified: Bousquet ⁷⁴
SLIT							
Seasonal allergic rhinitis							
Pre-/coseasonal SLIT is recommended for seasonal ARs for short-term benefit	I	A	I	A	Strong recommendation based on high-quality adult ⁸⁶⁻⁸⁹ and pediatric ^{90-92,155,156} studies.	Consistent results, low risk of severe systemic allergic side-effects.	Dhami 2017 ¹⁴ SR, for example, Adult: Dahl ⁸⁵ , Dahl ⁸⁶ , Dider ⁵⁶ , Durham ⁸⁷ , Palma-Carlos ⁹⁶ , Worm ⁸⁹ Pediatric: Blaiss ⁹⁹ , Bufe ⁹⁸ , Caffarelli ⁹⁰ , Halcken ⁹⁷ , Pajno ⁹¹ , Wahn ¹⁵⁶
Continuous SLIT can be recommended for seasonal AR for short-term benefit	I	A	I	A	Moderate-to-strong recommendation based on low ¹⁰⁰ and high ^{101,102} risk of bias adult studies plus low ¹¹¹ moderate ¹⁰³ and unclear ⁵⁷ risk of bias pediatric studies.	Some heterogeneity between studies particularly pediatric ones, low risk of severe systemic allergic side-effects.	Dhami ¹⁴ SR, for example, Adult: Amar ¹⁰⁰ , Ariano ¹⁰¹ , Creticos ⁹³ , Panzner ¹⁰² Pediatric: Bufe ¹⁰³ , Valovirta ⁵⁷ , Valovirta ¹¹¹
SLIT with aqueous solutions can be recommended for seasonal AR for short-term benefit.	I	B	I	A	Moderate recommendation for adults based on a mixture of low ¹⁰⁴ and high ^{101,105,106} risk of bias studies. Strong recommendation for pediatrics based on low risk of bias studies. ^{9,1,92}	Some heterogeneity between adult studies, low risk of severe systemic allergic side-effects.	Dhami ¹⁴ SR, for example, Adult: Ariano ¹⁰¹ , Bowen ¹⁰⁵ , Feliziani ¹⁰⁴ Pediatric: Pajno ⁹¹ , Stelmach ⁹²

(Continues)

TABLE 3 (Continued)

Recommendation	Adults		Children and adolescents		Strength of recommendation	Other considerations	Key references
	Evidence level	Grade of recommendation	Evidence level	Grade of recommendation			
SLIT with grass pollen tablets is recommended for AR for short-term benefit.	I	A	I	A	Strong recommendation based on low risk of bias adult ^{86,87,108,109} and pediatric ^{97-99,111} studies.	Nonimportant heterogeneity between studies, low risk of severe systemic allergic side-effects.	Dhami ¹⁴ , SR, e.g. Adult: Dahn ⁸⁶ , Didier ⁵⁶ , Didier ¹⁰⁸ , Durham ⁸⁷ , Durham ¹⁰⁹ Pediatric: Blaiss ⁹⁹ , Bufer ⁹⁸ , Halken ⁹⁷ , Valovirta ¹¹¹
Grass pollen SLIT tablets or solution with continuous therapy is recommended for AR for long-term benefit.	I	A	I	A	Strong recommendation for adults based on low risk of bias studies. ^{108,109} One low risk of bias pediatric study ^{110,111}	Effective up to 2 y after cessation in adults. ^{108,109} One pediatric study was designed to look at prevention of asthma.	Dhami ¹⁴ SR, e.g. Adult: Didier ⁹⁴ , Durham ¹⁰⁹ Pediatric: Valovirta 2011 ¹¹⁰ and 2017 ¹¹¹ Adult and pediatric: Ott ¹⁴⁵
Perennial allergic rhinitis							
SLIT with aqueous solutions may not be recommended for perennial AR for short-term benefit.	I	C*	I	A	*Weak recommendation against use for adults based on just one high risk of bias RCT so only a grade C recommendation. ¹⁰⁷ Cannot be recommended in children based on 4 negative RCTs and 1 positive RCT.	Low risk of severe systemic allergic side-effects. Studies of low ^{106,139,140,146} and high ¹⁴⁴ risk of bias suggest that it is not effective in children.	Dhami ¹⁴ SR, for example, Adult: Guez ¹⁰⁷ Pediatric: Bahçeciler ¹³⁹ , de Bot ¹⁴⁶ , Hirsch ¹⁴⁰ , Marcucci ¹⁴⁴ , Tari ¹⁰⁶
SLIT with HDM tablets is recommended for AR for short-term benefit.	I	A	I	A	Strong recommendation based on low risk of bias adult ⁵⁰⁻⁵⁴ and mixed adult/pediatric ^{51,55} studies.	Nonimportant heterogeneity between studies, low risk of severe systemic allergic side-effects.	Dhami ¹⁴ SR, e.g. Adult: Bergmann ⁵³ , Demoly ⁵² , Mosbech ⁵⁴ , Passalacqua ⁵⁰ , Passalacqua ¹⁴⁷ Adult and pediatric: Nolte ⁵¹ , Okubo ⁵⁵
HDM SLIT tablet with continuous therapy can be recommended for AR for long-term benefit.	I	B	-	C*	Moderate recommendation based on one large, low risk of bias study. ⁵³ No pediatric data.	One study demonstrates effectiveness for a year post-treatment ⁵³ ; data require replication especially as 3 y therapy required for grass pollen. *No pediatric data, extrapolated from adult data.	Adult: Bergmann ⁵³

Continuous: year-round therapy. Preseasonal: before a pollen season. Coseasonal: during a pollen season. Not all AIT preparations are licensed for children and adolescents. Long-term is defined as at least 1 y after cessation of the AIT course. See allergen factors section for other specific allergens.

TABLE 4 Recommendations: other approaches for allergen immunotherapy (AIT) for treatment of allergic rhinoconjunctivitis

Recommendation	Adults		Children and adolescents		Strength of recommendation	Other considerations	Key references
	Evidence level	Grade of recommendation	Evidence level	Grade of recommendation			
A combination of the TLR-4 agonist monophosphoryl lipid A with pollen allergoid is recommended for AR	I	A	III	B	Strong recommendation for adults based on 3 low risk of bias studies. ^{113,114,172} Weak recommendation for children. ¹³⁰	Consistent randomized controlled data; only one ragweed pollen study, others are grass and tree pollen. Only one uncontrolled before and after study pediatric study. ¹³⁰	Adult: Drachenberg ¹¹³ , DuBuske ¹¹⁴ , Drachenberg ⁹⁵ , Patel ¹⁷² Pediatric: Drachenberg ¹³⁰
Combining anti-IgE injections with AIT for AR is recommended for reducing side-effects	I	A	I	A	Strong recommendation based on one low risk of bias adult ¹¹⁷ and one low risk of bias pediatric ¹¹⁶ study.	Consistent evidence but the required length of cotherapy unclear.	Adult: Casale ¹¹⁷ Pediatric: Rolinck-Werninghaus ¹¹⁶
Recombinant AIT can be recommended for birch and grass pollen allergy	I	A	-	B	Moderate recommendation based on 2 double-blind placebo-controlled RCTs of unclear risk of bias. ^{75,119}	Some evidence of benefit for adults, no pediatric data.	Adult: Jutel ⁷⁵ , Paufl ¹¹⁹

for adults, B for children) and there are no head-to-head comparisons with conventional preparations. There is also 1 trial demonstrating efficacy for this approach with ragweed pollen¹⁷² and one with tree pollen.⁹⁵ The TLR-9 agonist (Bacterial DNA oligonucleotides containing a CpG motif) fused to Amb a 1, the major allergen of ragweed showed efficacy in a phase 2 trial¹¹⁵ although this was not observed in a subsequent phase 3 trial. The combination of anti-IgE injections with conventional and rush AIT with nonmodified extracts has been proven to be effective with a marked reduction in systemic side-effects in studies of children¹¹⁶ and adults¹¹⁷ (Grade A recommendation). This is an expensive approach, and there is concern as to when and how to discontinue the anti-IgE when AIT maintenance therapy is achieved.¹¹⁸

Recombinant AIT is attractive as it allows accurate standardization of allergen products, has potential for personalized therapy based on individual allergen sensitivities and a hypothetical lower risk of inducing new sensitizations. Subcutaneous recombinant birch (Bet v 1)¹¹⁹ and a five-recombinant grass allergen mix⁷⁵ have been shown to be efficacious with no safety concerns (Grade A for adults, B for children). However, there are no commercially products available at present. A recombinant B-cell epitope-based vaccine, comprising a recombinant hybrid grass allergen mix combined with a hepatitis B domain surface Pre-S protein as an immunologic carrier has shown efficacy in a phase 2 trial.¹²⁰ T-cell peptide immunotherapy for cat allergy using mixtures of short T-cell epitopes via the intradermal route had promising results in environmental chamber phase 2 studies¹²¹; however, it has been reported that a subsequent phase 3 study did not demonstrate effectiveness.¹²² Studies with other allergen peptide approaches are in progress.¹²⁴

There has been recent interest in the use of alternative modalities of delivery including the epicutaneous, intradermal and intralymphatic routes. In RCTs, epicutaneous grass pollen immunotherapy (EPIT) has shown modest benefit¹²⁵ although accompanied by local eczematous reactions at the patch application site. Intradermal grass pollen immunotherapy inhibited allergen-induced cutaneous late responses although in a subsequent RCT, it was ineffective and there was evidence of exacerbation of seasonal outcomes and Th2 inflammation in the skin.¹²⁶ The intralymphatic route, using a grass pollen extract and a modified cat allergen extract, showed efficacy in some trials^{127,128} but not in others.¹²⁹

5 | ALLERGEN FACTORS THAT MAY AFFECT THE EFFICACY OF AIT FOR AR

5.1 | Standardization of allergen extracts

For the common allergens, many companies now provide characterized, standardized, stable preparation for AIT as recommended by EMA.^{47,132} For others, such as molds, there are problems with the complexity, variability, and stability of the allergens.¹³³ The lack of standardized extracts may hamper the diagnosis of eligible patients for AIT and may impede the effectiveness of AIT.^{133,134} Additionally, nonstandardized preparations may vary between batches increasing

the potential for side-effects. Further purification and characterization of such allergens¹³⁴⁻¹³⁶ may result in better extracts for the future. Where possible, standardized allergen products should be used for AIT. Further discussion is available in a position paper on regulatory aspects of AIT.⁴⁷

5.2 | Formulation of SLIT preparations

In deciding on the appropriate preparation to use for AIT, the formulation should be taken into account. For example, 3 large studies have shown efficacy for HDM SLIT tablets,^{52,53,54} whereas 3 HDM SLIT studies with sublingual drops were negative,^{107,140,146} and another only demonstrated efficacy in the first and not the second year.⁵⁰ However, many factors such as differences in allergen content,¹⁴¹ administered volume, number of participants, and statistical power of the study may explain the differences between tablets and drop trials. We recommend that AIT products with evidence of efficacy in the clinical documentation should be used when they are available.

5.3 | Allergen mixtures

Both mixtures of grass pollen and mixtures of tree pollen are frequently used in AIT and such an approach is effective.¹⁴ The use of different, nontaxonomically related allergens mixed in 1 AIT product has been evaluated in a very limited number of studies. One SCIT study showed that a depigmented-polymerized mixed grass/birch pollen extract was effective over placebo.¹⁴² A small study in children demonstrated efficacy using a mixture of grass pollen and HDM SLIT.¹⁴³ SLIT drops that employed a monomeric *Phleum pratense* grass pollen extract was more effective when given alone compared to when given in an equivalent dose as part of a combination with a 9-pollen, multi-allergen, sublingual extract.¹⁰⁰

There are a number of potential drawbacks of mixing allergens including a dilutional effect, potential allergen degradation due to enzymatic activity of some allergens and the difficulties of adequately demonstrating efficacy of a high number of allergen combinations and/or different products. The EMA has recommended that only homologous allergens (usually ones that are taxonomically related¹³², for example, a mixture of grass pollen extracts⁵⁶) should be mixed and that allergens with enzymatic activity (e.g. HDM) should be never used in a mixture. We therefore recommend only homologous allergens to be mixed in AIT preparations until further evidence is available substantiating the efficacy of other mixtures (Grade A) (Table 5) (Table S1). Alternatively, extracts should be given separately.

5.4 | Specific allergens

In the recent meta-analysis, there were sufficient SCIT and SLIT studies for subgroup analyses by specific allergens.¹⁴ Short-term effectiveness was demonstrated for HDM (symptoms score SMD -0.73 ; 95% CI -1.37 , -0.10), grass pollen (-0.45 ; -0.54 , -0.36), tree pollen (-0.57 ; -0.92 , -0.21), and weed pollen (-0.68 ; -1.06 , -0.30).

However, there was substantial heterogeneity for all allergens, particularly molds (-0.56 ; -2.29 , 1.18), suggesting that different preparations may be more or less effective. Before a product is used, an individual product-based evaluation of the evidence for efficacy is recommended.

There are some orphan allergens where robust data from RCTs are sparse or nonexistent. Where there is a clinical need, the available evidence of efficacy and safety needs to be weighed against the needs of the individual patient. Where therapy is considered in the patient's best interest, an early evaluation of its impact on the patient's clinical symptoms is required to determine whether or not therapy should be continued. The generation of controlled clinical trial data to assess efficacy and safety of these orphan products should be encouraged. There will always be orphan allergens where such studies are uneconomic and have to be regulated as named patient products.⁴⁷

6 | PATIENT FACTORS THAT MAY IMPACT ON THE EFFICACY OF AIT FOR AR

The approach to immunotherapy is a good example of patient stratification. Immunotherapy will only work when directed to the specific allergen(s) driving symptoms. So identifying the driving allergen(s) with a thorough history and assessment of allergic sensitization is an essential example of patient stratification. Not all patients benefit from AIT¹⁴ and further stratification approaches to identify the responders would be useful.

6.1 | Polysensitized patients

Epidemiological data indicate that most patients with AR are polysensitized.¹⁴⁸ Consequently, consideration needs to be given as to whether patients are (i) clinically monoallergic (where only 1 allergen is driving symptoms) and polysensitized or (ii) poly-allergic (symptoms with overlapping exposure to multiple different allergens) and polysensitized. Immunotherapy with a single allergen extract is effective in the first,¹⁴⁹ while immunotherapy has been shown to be ineffective¹⁵⁰ or less effective in the last situation.¹⁵¹ This may be apparent from the history or may need investigation with component-resolved diagnostics or assessment with nasal or conjunctival provocation challenges where the clinician is experienced in these diagnostic procedures.¹³⁷ Polysensitized patients who are monoallergic are recommended to receive AIT for the specific allergen that is driving their AR symptoms (Grade A).

For a polysensitized patient who is poly-allergic for homologous (biologically related) allergens (e.g. 2 grass pollens), a single allergen preparation or a mixture of 2 homologous allergens is recommended (Grade B).¹³⁷ For poly-allergic patients where allergens are not homologous, separate AIT preparations for 1 or 2 of the clinically most important allergens might be recommended with doses given 30-60 minutes apart at separate locations when 2 are selected (Grade C).^{32,137} This represents a trade-off between efficacy and

TABLE 5 Recommendations: allergen factors that affect the efficacy of AIT for allergic rhinoconjunctivitis

Recommendation	Children and Adolescents		Strength of recommendation	Other considerations	Key references
	Adults Evidence level	Evidence level			
Either a single allergen species or a mixture of well-documented homologous allergens from the same biological family are recommended for patients with AR who are allergic to grass pollens, tree pollens, or HDM	I	I	A	Strong RCT evidence that these are effective approaches. Supported by regulators.	Demoly ¹³⁷ , Dhimi ¹⁴ , EMA ¹³² Adult: Balda ⁶⁹ , Bodtger ⁷⁰ , Charpin ⁶¹ , Dahl ⁸⁵ , Didier ⁵⁶ , Ott ¹⁴⁵ , Passalacqua ¹⁴⁷ , Varney ⁶⁶ , Varney ⁷¹ Pediatric: Bufe ⁹⁸
Mixtures of allergens from nonrelated biological families are not recommended for AIT.	I	—	C*	Strong recommendations on basis of low risk of bias grass pollen (single grass, e.g. ^{85,98,99}); mixture of grasses, e.g. ^{56,145}), tree pollen (single tree, e.g. ^{61,70}); mixture of trees, e.g. ⁶⁹ and house dust mite (single, e.g. ⁶⁶ ; mixture, e.g. ¹⁴⁷) studies.	Bonertz ⁴⁷ , EMA ¹³² Adult: Amar ¹⁰⁰ , Nelson ¹⁵¹ , Pfaar ¹⁴²

Examples of homologous, taxonomically related allergens from the same biological family are the grasses or tree pollens. Also see Table 3.

safety as both seem to be dose-dependent. More studies are needed to further address this important clinical challenge.

6.2 | Co-existing asthma

Co-existing asthma is seen in many participants in the published AR AIT studies.¹⁴ Co-existing asthma has no impact on the efficacy of AIT for AR¹⁰³ and may also lead to improvement in asthma.⁴³ When controlled, mild-to-moderate asthma does not seem to be a safety issue with AIT (Grade A recommendation).^{41,43} In 1 large recent asthma SLIT trial, participants with not well-controlled asthma based on an Asthma Control Questionnaire (ACQ-6) were included safely in the study.⁴¹ We await confirmatory evidence and emphasize that efforts should be taken to control asthma before commencing AIT. Uncontrolled or severe asthma are definitely considered to be an absolute contraindication to AIT.²⁵⁻³¹

6.3 | Specific pediatric issues

Similar to adults, AIT should be considered in pediatric patients with AR with evidence of IgE sensitization to clinically relevant allergens (Grade A) (Tables 1 and 3).

The evidence for the efficacy of AIT for AR is limited in children younger than 5 years of age. Some clinical studies have shown the efficacy and safety of both SCIT and SLIT in preschool children,^{88,152-155} and children were included from 5 years onward in several of the well-powered SLIT tablet trials.^{98,156} Experience suggests that repeated injections of SCIT may be stressful in preschool children. It is recommended that the decision to start the treatment has to be taken on a case-by-case basis together with the patients and their family (Grade D). The decision should depend on several factors, such as the severity of the allergic disease, the clear exposure-symptoms pattern supported by allergic sensitization testing, the impairment of the health-related quality of life and the expected acceptance and adherence to the AIT.

There are more data to drive recommendations for school age children and adolescents although major gaps still exist (Table 3). Many of the SCIT trials are now relatively old, many enrolled only a few children and/or did not present pediatric only analyses. Continuous and pre- and pre/coseasonal SCIT can be recommended (Grade B) for children with seasonal AR (Table 3). Continuous SCIT is also recommended for perennial AR but with a weaker grade due to the lack of exclusive pediatric data (Grade C) (Table 3). There are no exclusive pediatric, placebo-controlled data for allergoid preparations, but 1 controlled trial with a preseasonal treatment regimen has indicated long-term efficacy of preseasonal grass pollen immunotherapy in this age group.¹⁵⁷ Two further open RCTs also suggest that SCIT for grass pollen-driven AR does have a long-term benefit.^{63,158}

For SLIT, there are more recent pediatric trial data to support this approach. In general, pre-/coseasonal and continuous SLIT is recommended for seasonal AR (Grade A) (Table 3). Both tablet and aqueous formulations are recommended (Grade A) (Table 3). There is now one recently published trial supporting the long-term

effectiveness for a grass pollen tablet and reduction in asthma symptoms^{110,111} (Grade A). For perennial allergic rhinitis, the evidence is not as good. There are no consistent data to recommend SLIT with aqueous solutions for perennial allergic rhinitis, but the SLIT tablet approach has been demonstrated to be effective in the short term in mixed adult/adolescent studies^{51,55} (grade A).

6.4 | Elderly

A detailed allergy history is especially important when evaluating older adults suffering with rhinitis as other types of rhinitis may mimic AR symptoms. There are very few studies specifically evaluating the use of AIT in the elderly (defined here as >65 years as this is usually exclusion criteria in AIT trials) but SLIT with grass pollen and HDM has been demonstrated to be effective and safe in 2 studies.^{159,175} AIT elicits clinical responses comparable to studies with younger patients. Another important consideration in this age group, when contemplating treatment with AIT, is the higher prevalence of comorbidities. Examples are hypertension, coronary artery disease, cerebrovascular disease, malignancy and/or cardiac arrhythmias. Also, treatment with medication such as beta-blockers may impair the treatment of anaphylaxis with adrenaline (epinephrine) (see Table 2). AIT can be recommended in otherwise healthy elderly patients with AR whose symptoms cannot be adequately controlled by pharmacotherapy (Grade A for SLIT, B for SCIT).

6.5 | Pregnancy

There is 1 prospective study investigating the safety of AIT in pregnancy¹⁶¹ and several retrospective studies that suggest that there is no greater risk of prematurity, fetal abnormality, or other adverse pregnancy outcome in women who receive AIT during pregnancy.³⁹ Observations about anaphylaxis in pregnant and breastfeeding women are largely derived from case reports and are generally reassuring.¹⁶² However, the balance between benefits and potential risks in pregnant patients needs to be discussed with the patient. Systemic reactions and their resultant treatment can potentially harm the baby and/or mother. It is therefore recommended that AIT is not initiated during pregnancy (Grade D) but, if already initiated, AIT may be continued during pregnancy or breastfeeding in agreement with the patient's general practitioner (GP) and obstetrician if former AIT treatment has previously been tolerated well (Grade C).

6.6 | Adherence

There is a great variance between studies (both real-life studies and clinical trials) in the criteria used for evaluating adherence and in the rates of adherence.¹⁶³⁻¹⁶⁹ The range of reported adherence varied from 18% to over 90%, higher in clinical studies than real-life surveys with overlapping ranges for SCIT and SLIT. The main causes for poor adherence are reported to be side-effects, inconvenience, lack of efficacy or forgetting to use.^{163-165,167,168,170} A few other factors

TABLE 6 Recommendations: patient factors that affect the efficacy of allergen immunotherapy (AIT) for allergic rhinoconjunctivitis

Recommendation	Evidence level	Grade of recommendation	Strength of recommendation	Other considerations	Key references
Polysensitized patients					
Polysensitized patients who are monoallergic are recommended to receive AIT for the specific allergen that is driving their AR symptoms	I	A	Strong recommendation, based on RCTs with low risk of bias ^{56,109}	Expert review of RCTs ^{137,149}	Didier ⁵⁶ , Demoly ¹³⁷ , Durham ¹⁰⁹ , Nelson ¹⁴⁹
Polysensitized patients who are poly-allergic for taxonomically related homologous allergens can be recommended to receive either a single allergen or a mixture of homologous allergens from that biological family that covers all the major allergens	II	B		Expert review of RCT data	Demoly ¹³⁷ , EMA advice ¹³²
Patients who are poly-allergic for nonhomologous allergens may be recommended to start AIT with either the allergen responsible for most of their allergic rhinoconjunctivitis symptoms or separate treatment with the 2 clinically most important allergens	II	C		Expert review of RCT data	Demoly ¹³⁷ , EMA advice ¹³² , Pfaar ¹⁴²
Co-existing asthma					
Controlled asthma is not a contraindication to AIT	I	A	Strong recommendation based on low risk of bias studies ⁴³	Evidence described in asthma AIT systematic review. ⁴³	Dhimi ¹⁴ , Virchow ⁴¹ , Dhimi ⁴³
Specific pediatric issues					
Consideration of AIT is recommended in pediatric patients with AR with evidence of IgE sensitization to clinically relevant allergens	I	A	Strong recommendations from low risk of bias studies [e.g 90,91,92,98]	See Table 3 for detailed review.	Bufe ⁹⁸ , Caffarelli ⁹⁰ , Pajno ⁹¹ , Steilmach ⁹²
In children aged 2-5 y of age, it may be recommended that consideration should be given to likely benefits and risks associated with AIT for AR	IV	D	Weak recommendation based on little available evidence	May be more difficult to make a definitive diagnosis of AR in preschool children. Safety seems to be similar in this age group as per older patients.	Rienzo ¹⁷³ , Rodriguez-Santos ¹⁷⁴
Elderly					
AIT can be recommended in otherwise healthy elderly patients (>65 y) with AR	I	A (SLIT), B (SCIT)	Moderate recommendation for SLIT based on 2 consistent RCT studies of unclear risk of bias. ^{159,175} Moderate recommendation for SCIT based on only one relatively small, low risk of bias study. ¹⁶⁰	Detailed clinical assessment is recommended to exclude other types of rhinitis in elderly patients.	Bozek 2012 ¹⁷⁵ , 2014, ¹⁵⁹ 2016 ¹⁶⁰
Pregnancy					
Immunotherapy is not recommended to be initiated during pregnancy	V	D		Based on balance of additional risk vs benefits.	Expert opinion

(Continues)

TABLE 6 (Continued)

Recommendation	Evidence level	Grade of recommendation	Strength of recommendation	Other considerations	Key references
Maintenance immunotherapy may be recommended to be continued (at the achieved dose) during pregnancy	III	C	Weak recommendation based on one cohort study ¹⁶¹ and one case series ⁴⁰		Shaikh ^{1,61} , Metzger ⁴⁰
Adherence					
It is recommended that patients should be informed about how immunotherapy works and the need to take regular doses and complete the course of treatment.	IV	C	Based on a survey of allergists.	Based on observational data	Scurati ¹⁶⁴
Reminders are recommended for patients on immunotherapy to improve treatment adherence.	III	C	One interventional study (educational session, phone calls, emails)	Consider mobile phone texts, social media, and applications (apps)	Savi ¹⁶⁹
Patients receiving SLIT can be recommended to be followed up every 3 mo to improve treatment adherence	II	B	Moderate recommendation based on one quasi-randomized study. ¹⁷¹	Method of randomization unclear.	Vita ¹⁷¹

have been associated with poor adherence, for example, age and patient's educational level. Potential ways to improve adherence are the use of reminder mechanisms (e.g. alarm on mobile phone, Internet-based tools, short message service (SMS) electronic reminders, social networks, mobile applications (apps), and monitoring systems—this approach should be tailored to the patient (Grade C). Patient education and good communication between physician and patient are key (Grade C).¹⁶⁹ One randomized study suggests that adherence is much better with 3-monthly follow-up appointments compared to 6 or 12-monthly follow-up (Grade B).¹⁷¹ Recommendations are summarized in Table 6.

7 | HOW LONG AIT SHOULD BE CONTINUED FOR IN AR?

Most clinical studies evaluating the efficacy of AIT follow participants for 1 or 2 years on therapy. The EMA currently recommends an experimental, randomized, controlled design involving 3 years of therapy with a 2-year follow-up period off treatment. These studies demonstrate a sustained benefit for 3 years of SLIT-tablet grass pollen therapy for 2 years off therapy.^{94,109,111,176} There are some data to suggest that HDM SLIT tablets give sustained benefit for at least 1 year after 1 year of therapy in 1 RCT⁵³ and also after 3 years of therapy in a SLIT drop RCT.¹⁷⁷ More data are required for HDM, and evidence is required on the optimal duration of therapy. Grass pollen SCIT for 3-4 years has been shown to result in long-term efficacy for 3 years after discontinuation.⁸³ In a recent study, either SCIT or SLIT tablets were effective compared to placebo over 2 years, but 2 years were insufficient for long-term efficacy as measured 1 year off treatment.⁶⁵ In another adult study, participants randomized to 3 years of ragweed continued to benefit after 2 years post-SCIT.¹⁷⁸ Similarly, children randomized to 3 or 5 years HDM SCIT had similar outcomes at 5 years.¹⁷⁹ So, in summary, for patients with AR, a minimum of 3 years of AIT is recommended to achieve long-term efficacy after treatment discontinuation (Grade A) (Table 7).

8 | ADVERSE EVENTS WITH AIT FOR AR

8.1 | SCIT

Subcutaneous immunotherapy is a safe and well-tolerated treatment when the injections are given in a medical setting by experienced personnel trained in the early recognition of systemic reactions and how to manage them (Table 8).^{11,180-182} There must be immediate access to resuscitation equipment and a physician trained in the management of anaphylaxis (Grade C).

Systemic allergic adverse reactions to SCIT can range between mild-to-severe adverse reactions of the skin, upper and lower airways, gastrointestinal tract, or the cardiovascular system (see Table S2 in online supplement for details of classification).¹²³ In a 3-year real-life US survey study that included over 20 million injection

TABLE 7 Recommendations: how long should AIT for allergic rhinoconjunctivitis be continued?

Recommendation	Evidence level	Grade of recommendation	Strength of recommendation	Contextual comments	Key references
AIT is recommended as benefit is seen from the first year of therapy	I	A	Strong recommendation based on low risk of bias studies (e.g. ^{53,56,58,69,72,74,85,94})	Generally consistent data	Dhami ¹⁴ , Bergmann ⁵³ , Bousquet ⁷⁴ , Didier ⁹⁴ , Dahl ⁸⁵ , Frew ⁵⁸
It is recommended that to achieve long-term benefits, immunotherapy should be continued for a minimum of 3 y	I	A	Strong recommendation based on low risk of bias long-term adult studies, ^{56,56,83,84,94,108,109,145} one high risk of bias pediatric study (due to its open design although it was randomized) ⁶³ plus one recently published low risk of bias pediatric study. ¹¹¹	Consistent data	Adult: Arroabarren ¹⁷⁹ , Didier ⁵⁶ , Didier ¹⁰⁸ , Didier ⁹⁴ , Durham ⁸³ , Durham ¹⁰⁹ , James ⁸⁴ , Lin ¹⁷⁷ , Naclerio ¹⁷⁸ , Ott ¹⁴⁵ , Scadding ⁶⁵ Pediatric: Jacobsen ⁶³ , Stelmach ²²³ , Valovirta ¹¹¹

visits, systemic reactions were reported in 0.1% of injections; there were no fatalities¹⁸² although 4 were reported in a follow-up survey by the same group.¹⁸³ Fatal allergic adverse reactions have though been reported in earlier surveys.^{30,31} Over 80% of reactions occurred within 30 minutes after injection; very few of the delayed ones were severe. It is therefore recommended that patients stay in clinic for at least 30 minutes after an injection (Grade C).

A European real-life, prospective, survey performed by members of the Immunotherapy Interest Group of EAACI on 4316 patients in France, Germany, and Spain was published after our SR was completed.^{184,185} It demonstrated that SCIT and SLIT for respiratory allergy are safe in general in the pediatric and adult population and found only a low number of systematic reactions (SRs). For SCIT, SRs were found in 2.1% of all SCIT-treated patients. Independent risk factors for SRs during SCIT were the use of natural extracts, the absence of symptomatic allergy medications, asthma diagnosis, sensitization to animal dander or pollen, cluster regimens (vs rush), and a previous episode of anaphylaxis. Further possible risk factors for systemic adverse reactions have been described (Box 3¹¹). When 1 or more severe adverse reactions occur, the allergist (specialist and subspecialists) should re-evaluate the benefits and risks of SCIT therapy with the patient and decide whether or not treatment should be continued (Grade D). In any case, cessation of treatment or adaptation of the dosing schemes for the next injection should follow the summary of product characteristics (SmPC).

Redness, itching, or swelling represents local reactions at the injection site and occurs frequently after around half of injections.¹⁴ Local measures (e.g. cooling or topical glucocorticoids) or oral antihistamines may be helpful for these reactions. Increased local adverse reactions do not predict an increased individual risk of a systemic adverse reaction.¹⁸⁶ In case of enlarged local adverse reactions (redness and/or swelling >10 cm in diameter) occur at the injection site, the SmPC provides adaptation of the dosing schemes for the next injection. When local adverse effects occur, premedication with an H1-antihistamine can be used to reduce the frequency and severity of adverse reactions (Grade A recommendation), but this prophylactic treatment does not prevent the onset of SRs or anaphylaxis.^{187,188} Also, studies indicate that modified allergen extracts are

associated with less adverse effects.¹⁸⁹⁻¹⁹² For aluminum hydroxide containing SCIT products, granulomas have been described from a foreign body reaction mainly caused by incorrect intradermal administration as well as contact allergic reactions, new onset of protein contact dermatitis, or a vasculitis inflammatory reactions have been reported.¹⁹³⁻¹⁹⁵ If these reactions to SCIT occur, treatment with another aluminum hydroxide-free product is preferred (Grade D).¹¹

8.2 | SLIT

Sublingual immunotherapy is regarded to be a safe and well-tolerated treatment (Table 8).^{11,14,196,197,198}

Severe SRs with SLIT appear to be much less likely than with SCIT although the overall rate of any adverse reactions is similar in both SCIT and SLIT^{14,184} (see Tables S2 and S3 in online supplement for details of classification^{123,199}). In a review of 66 SLIT studies (over 4000 patients who received over a million doses), there was 1 SR for approximately every 4 years of treatment and only 1 severe SR per 384 treatment years.¹⁹⁸ There are no new safety concerns in more recent studies.¹⁴ Several severe reactions—in some cases with anaphylaxis—are described in the literature occurring within 30 minutes of sublingual administration of allergens in droplet or tablet form.³⁴ In these cases, SLIT was not administered according to the standards (nonstandardized extracts, rush protocols, excessive allergen dose, patients in whom SCIT had previously been interrupted due to severe reactions). Patients should be observed for at least 30 minutes after the first dose (Grade C) and supervised by staff able to manage anaphylaxis (Grade C). As in SCIT, concomitant, uncontrolled asthma has been reported to be associated with severe systemic reactions after SLIT.³⁴ In the recently published European Survey, the rate of SRs under SLIT was also reported to be low (1.1% of all SLIT-treated patients).^{184,185}

The majority of adverse events in SLIT develop at home without any medical observations. Patients should therefore be thoroughly informed about how to recognize and manage reactions, particularly severe ones (Grade D). Patients also need education on what to do if a dose is forgotten and when SLIT should be temporarily interrupted (e.g. oropharyngeal lesions) (Grade D).¹¹ When 1 or more

severe adverse reactions occur, the allergist (specialist and subspecialists) should rediscuss the benefits and risks of SLIT with the patient and decide whether or not treatment should be continued (Grade D). As for SCIT, cessation of treatment or adaptation of the dosage should follow the summary of product characteristics (SmPC).

The frequency of local adverse events during SLIT correlates with the dosage and has been reported to be 40-75%, for example, temporary local mucosal reactions (oral pruritus or dysesthesia, swelling of the oral mucosa, throat irritation) or abdominal pain.^{34,197-199} Most of these reactions occur during the initial phase of the treatment course (commonly in the first 3 weeks). They are commonly considered to be of mild intensity and self-limiting.^{34,97} Nevertheless, these reactions may lead to cessation of treatment, as observed in 4-8% of cases reported in recent trials of SLIT tablets.^{56,85,99,138} (see section "adherence"). As in SCIT, local adverse reactions may be diminished by the intake of oral antihistamines (Grade A).

For SLIT, temporary cessation of therapy may be advised in a number of situations to reduce the potential for adverse effects. For example, for 7 days following dental extraction or oral surgery or following shedding of a deciduous tooth; while an oral ulcer or open wound in the mouth heals; or during an upper respiratory tract infection in patients with asthma. Individual product SmPCs may list additional advice.

9 | PREVENTIVE EFFECTS OF AIT FOR AR

A 3-year course of AIT reduces the likelihood that children and adolescents with allergic rhinitis driven by pollen allergy go on to develop asthma up to 2 years post-AIT.²³ There is currently no convincing evidence for a preventive effect of HDM AIT or for prevention of new sensitivities.²³ This is further discussed in the EAACI AIT Prevention Guidelines.²³

10 | PHARMACOECONOMIC ASPECTS OF AIT VERSUS PHARMACOTHERAPY FOR AR

Pharmacoeconomic studies that only analyze costs in monetary units have reported beneficial healthcare expenditure of AIT in the long-run although savings are not expected in the first year. The majority of pharmacoeconomic studies support the viewpoint that AIT gives value for money, with cost-effectiveness within 6 years of treatment initiation.²⁰¹ Retrospective and prospective observational studies have shown that SCIT and SLIT positively affect healthcare expenditure in pharmacotherapy with a reduction in expenditure of 12% to 80%.²⁰²⁻²⁰⁶ A reduction in medical costs in the AIT vs placebo groups has been repeatedly reported, but these savings did not compensate the costs of AIT.^{202,207,208}

In contrast to cost-only studies, cost-effectiveness and cost-utility analysis evaluate the effects of treatment in terms of clinical

benefits or health-related quality of life (i.e., quality-adjusted life years [QALYs]). An incremental cost-effectiveness ratio (ICER), which is defined as costs divided by benefits, can be calculated to estimate the costs of a certain gain. Several health economics studies that include cost-effectiveness and cost-utility calculations have demonstrated that SCIT and SLIT are economically advantageous to pharmacotherapy.²⁰⁹⁻²¹²

Seven studies based on RCT data conducted from a health system perspective and using QALYs as their outcome measure suggests that SLIT and SCIT would be considered cost-effective in this patient population in United Kingdom at the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold of £20 000 (€24 616) per QALY.²¹³⁻²¹⁹ The studies comparing SCIT and SLIT have given mixed results and do not allow us to conclude whether either treatment is more cost-effective.²²⁰ ICERs for cost evaluations of AIT seem to vary substantially between different health systems suggesting that straightforward conclusions may not be generalizable even across seemingly similar countries.²¹⁵ Finally, the quality of the studies and the general lack of attention to characterizing uncertainty and handling missing data should be taken into account when interpreting these results.

11 | SUMMARY, GAPS IN THE EVIDENCE AND FUTURE PERSPECTIVES

The EAACI Taskforce on AIT for AR has developed this guideline as part of the EAACI AIT Guidelines Project. This guideline has been informed by a formal SR and meta-analysis of AIT for AR.¹⁴ The guidelines provide evidence-based recommendations for the use of AIT for patients with AR with or without allergic conjunctivitis. A comparison of SCIT and SLIT is provided in Figure 2. Practical guidance is provided in Box 4 and a summary of the guidelines is provided in Box 5. An approach to the use of AIT for AR across the healthcare system is summarized in Figure 3. The recommendations should be of value to all healthcare professionals involved in the management of patients with AR. There are barriers to the wider use of AIT but equally there are facilitators that could be put into place to widen access to AIT (Table 9).

The key limitation of this guideline is the considerable heterogeneity seen in elements of the underpinning meta-analysis. For newer products, such as the SLIT grass pollen and house dust mite tablets, we have consistent low risk of bias data and very secure recommendations. For older products, such as house dust mite SCIT products, there is considerable heterogeneity in the meta-analysis weakening the strength of recommendations around those products. Many of these older studies were poorly designed and reported; for example, it is often not clear whether intention-to-treat or per-protocol analyses were being reported making it impossible to combine similar analyses in the meta-analysis. Indirect comparisons within the meta-analysis strongly suggest that some products are more effective than others. A network analysis approach, which allows indirect comparisons across trials based on a common comparator (usually

TABLE 8 Recommendations: adverse events with allergen immunotherapy (AIT) for allergic rhinoconjunctivitis

Recommendation	Evidence level	Grade of recommendation	Strength of recommendation	Contextual comments	Key references
SCIT or SLIT					
For correctly selected patients, SCIT or SLIT is recommended as, appropriately administered, it is safe and well tolerated	I	A	Strong recommendation based on low risk of bias RCT studies and observational studies ^{1,4}	Consistent evidence	Dhami ¹⁴
It is recommended that asthma should be controlled before commencing AIT as insufficiently controlled asthma is a risk factor for both SCIT and SLIT	III	C		Expert opinion from observational studies	Bernstein ³¹ , Amin ²⁰⁰ , Calderon ³⁴
Premedication with an antihistamine is recommended as it reduces the frequency and severity of local and systemic cutaneous reactions but does not eliminate the risk of other systemic adverse reactions including anaphylaxis	I	A	Strong recommendation based on low risk of bias RCTs. ^{187,188}	Consistent strong evidence from RCT studies	Nielsen ¹⁸⁷ , Reimers ¹⁸⁸
When one or more severe adverse reactions occur, it may be recommended that the allergist (specialist and subspecialists) should rediscuss the benefits and risks of AIT therapy with the patient and decide whether or not treatment should be continued. This decision and continuation of treatment should be in line with the Summary of Product Characteristics (SmPC).	V	D		Expert opinion from clinical experience	Expert opinion
SCIT					
It is recommended that patients should remain under observation for at least 30 min after a SCIT injection	III	C		Consistent observational data	Epstein ¹⁸²
If subcutaneous granulomas develop with aluminum hydroxide containing SCIT products, it may be recommended that a replacement allergen extract that does not contain aluminum hydroxide should be used.	V	D		Expert opinion	Pfaar ¹¹
It is recommended that SCIT should be administered by competent staff with immediate access to resuscitation equipment and a doctor trained in managing anaphylaxis.	III	C		Consistent observational data on adverse effects reported in SR	Dhami ¹⁴
SLIT					
It is recommended that patients should remain under observation for at least 30 min after an initial SLIT dosage	III	C		Expert opinion based on consistent observational data	Calderon ^{3,4}
It is recommended that initial SLIT dosage should be administered by competent staff with immediate access to resuscitation equipment and a doctor trained in managing anaphylaxis.	IV	C		Consistent observational data on adverse effects reported in SR	Dhami ¹⁴
It is recommended that patients receiving SLIT should be informed about how to recognize and manage reactions, particularly severe ones. Patients also need to know what to do if a SLIT preparation is forgotten and when SLIT should be temporarily interrupted (e.g. oropharyngeal lesions).	V	D		Expert opinion from clinical experience	Expert opinion

BOX 3 Risk factors for systemic reactions during AIT

- Current allergy symptoms and potential allergen exposure
- Current infections
- Mast cell disease
- Previous systemic reaction to SCIT or SLIT
- Uncontrolled or severe asthma
- A high degree of sensitization
- Excess dose escalation during initiation
- Beta-blockers use
- Poor injection technique
- Overdose of allergen extract
- Failure to follow manufacturer's recommendation for dose reduction when change to new production batch
- High-intensity physical exercise

Adapted from Pfaar et al.¹¹.

the placebo group), would allow us to improve our comparative estimates between products.²²¹ This would allow product-specific recommendations to be made. The different local regulations⁴⁷ and availability of products⁴⁸ makes this difficult at a European level. So before treatment with a specific product is initiated, clinicians need to undertake an individual product-based evaluation of the evidence for efficacy, focusing on low risk of bias studies which are generally the larger, more recent ones.¹¹

There are a number of areas in this guideline where there is no low risk of bias evidence, and these signify the gaps in the current evidence base. The key ones are highlighted here and in Table 10. There is a major gap in the evidence base for the clinical effectiveness of AIT in children and adolescents with recommendations at least 1 grade lower than for adults in most areas. As AR usually starts in childhood and AIT has the potential to change the natural course of the disease and prevent the development of asthma, this age group has most to benefit. Once safety is established in adult studies, pediatric studies need to be commenced using validated, common outcome measures.¹¹ There are also little data in the

AIT should be considered if all are present:

- Moderate-to-severe symptoms of allergic rhinitis, +/- conjunctivitis, on exposure to clinically relevant allergen(s)
- Confirmation of IgE sensitisation clinically relevant allergen(s)
- Inadequate control of symptoms despite antihistamines and/or topical corticosteroids and allergen avoidance measures and/or unacceptable side-effects of medication


Pros and cons of the various options need to be considered when choosing the best approach for each patient:

FIGURE 2 Schematic approach to deciding which approach to allergen immunotherapy (AIT) is best to use in individual patients. For details to specific recommendations, see table 3. For details about local and systematic adverse reactions, see adverse event section above

BOX 4 Practical considerations for healthcare professionals delivering AIT

- Training and facilities
 - Expertise in the diagnosis and differential diagnosis of AR by history and supporting SPT or specific IgE testing.
 - Training in recognition and management of severe allergic reactions including anaphylaxis.
 - Availability of equipment and trained personal to manage severe allergic reactions.
 - Training in administration of specific AIT products.
 - Facilities to observe patient for at least 30 minutes with SCIT injections and initial dose of SLIT.
- Assessing patient and deciding on best approach
 - Effective communication with patients and/or family about practicalities of AIT, expected benefits and potential adverse effects.
 - Identification of clinical contraindications to AIT.
 - Select an AIT product with documented evidence for efficacy and safety, for the patient's specific presentation, wherever possible.
- Undertaking AIT
 - Start AIT for seasonal AR at least 4, and preferably 2, months before the pollen season.
 - Preferably start AIT for perennial AR when allergen exposure is lowest and avoidance measures are in place.
 - Dose reductions (usually 50%) or split doses for adverse effects, intercurrent illness, or delayed dosing as recommended by SmPC for SCIT.
 - Dose interruption with oral lesions and other issues as recommended by SmPC for SLIT.
 - Facilities to regularly follow up patient promoting adherences to therapy and watching for adverse effects.

elderly particularly for patients with multimorbidity. Additionally, more RCTs need to follow participants postcessation of therapy to establish long-term clinically effectiveness, especially for HDM respiratory allergy. Dose-finding studies are needed. Agreement about the clinically meaningful effect size of AIT treatment would assist in the interpretation of clinical trial data and help facilitate stratification studies to help predict which patients will respond best to which forms of AIT. The collection of patient-reported outcomes in studies would ensure the patient experience is captured. Additionally, we need data from randomized cost-effectiveness and cost-utility studies to use in discussions with healthcare funders. We need biomarkers to predict and quantify the effectiveness of AIT to assist in patient selection.²²² Suboptimal adherence with AIT is likely to

impact on its effectiveness; novel approaches to improve effectiveness should be developed in partnership with patients. Also, to allow better comparison of safety between approaches, studies need to use a unified approach to classifying side-effects is required. A common and international recognized language should be used when reporting severe adverse reactions, such as the MedDRA classification and AIT-related local and systemic reactions should be reported in line with internationally standardized classification such as the WAO-grading system.^{123,199} Filling these gaps would allow the generation of much clearer guidelines for clinicians allowing them to stratify patients to the best therapy. It may not be possible to achieve this with only randomized, controlled prospective data; large, real-life, controlled data need to be examined although the potential for bias and confounding needs to be acknowledged.

Despite all these gaps, we have clear evidence for the clinical effectiveness of AIT, for SCIT, SLIT tablets, and SLIT drops, for adults and children with moderate-to-severe AR that is otherwise uncontrolled despite pharmacotherapy. We have evidence-based recommendations for specific patient groups and specific approaches. There is now a need to ensure that primary care healthcare professionals know which patients might benefit from AIT (Box 6), that national healthcare providers understand that AIT is cost-effective and that patients and patient support groups are aware of this approach. This will be supported by the implementation strategy for this guideline with efforts being put into disseminating the guideline. This will be supported with materials such as schedules and country-specific product evaluations as exemplified by the German, Austrian, and Swiss guideline.¹¹ Finally, as new evidence is published, these guidelines will need to be updated with revision of specific recommendations to reflect the new data.

ACKNOWLEDGMENTS

The EAACI Guideline: AIT for rhinoconjunctivitis Taskforce would like to thank Kate Crowley and Lynn Reeve for their administrative assistance; Stefan Vieths and Andreas Bonertz for their advice; Claus Bachert, G. Walter Canonica, Gabriele Di Lorenzo, Peter Eng, Hans Joergen Malling, and Harold Nelson for their constructive, expert review of the draft guidelines; all the EAACI members who commented on the draft guideline via the public Web site; and to funding from EAACI and the BM4SIT project (grant number 601763) in the European Union's Seventh Framework Programme FP7.

AUTHOR CONTRIBUTIONS

G Roberts and O Pfaar jointly chaired the EAACI Guideline: AIT for rhinoconjunctivitis Taskforce; together with A Muraro and A Sheikh, they conceptualized the manuscript. CA Akdis, IJ Ansotegui, SR Durham, R Gerth van Wijk, S Halcken, D Larenas-Linnemann, R Pawankar, C Pitsios, A Sheikh, and M Worm all initially drafted sections of the guideline. S Arasi, M Calderon, C Cingi, S Dhimi, JL

BOX 5 Summary of the EAACI Rhinoconjunctivitis AIT Guidelines

- AIT should be considered with symptoms strongly suggestive of allergic rhinitis, with or without conjunctivitis; evidence of IgE sensitization to 1 or more clinically relevant allergens; and moderate-to-severe symptoms despite regular and/or avoidance strategies.
- AIT may also be considered in less severe AR where a patient wishes to take advantage of its long-term effect on rhinitis and potential to prevent asthma with grass pollen AIT.
- More standardized products with documented evidence for efficacy in clinical trials are needed.
- Standardized AIT products with evidence of efficacy in the clinical documentation should be used when they are available.
- An individual product-based evaluation of the evidence for efficacy is recommended before treatment with a specific product is initiated.
- Key contraindications are severe or uncontrolled asthma; active, systemic autoimmune disorders; active malignant neoplasia. Careful review of benefits and risks is required with history of severe reactions, beta-blocker therapy, severe cardiovascular disease, other autoimmune disorders, severe psychiatric disease, poor adherence, and immunodeficiency. The individual patient's conditions should be considered when deciding whether to prescribe AIT and the summary of product characteristics (SmPC) should be reviewed for specific contraindications for individual preparations.
- For each recommendation, an individual product-based evaluation of the evidence for efficacy is recommended before treatment with a specific product is initiated given the heterogeneity in meta-analysis results:
 - Continuous SCIT is recommended for seasonal (Grade A for adults, B for children) or perennial (Grade B for adults, C for children) AR for short-term benefit in those with moderate-to-severe disease.
 - Pre- and pre-/coseasonal SCIT is recommended for seasonal AR for short-term benefit (Grade A for adults, B for children).
 - Both modified (allergoids) and unmodified allergen SCIT extracts are recommended for AR for short-term benefit (Grade A for adults, B for children).
 - Continuous grass pollen SCIT is recommended for AR for short- and long-term benefit (Grade A for adults, B for children).
 - Pre-/coseasonal or continuous SLIT is recommended for seasonal ARs for short-term benefit (Grade A).
 - SLIT with tablets for pollens or HDM can be recommended for AR for short-term benefit (Grade A).
 - SLIT aqueous solutions for pollens can be recommended for AR for short-term benefit (Grade B for adults, A in children).
 - SLIT aqueous solutions for HDM cannot be recommended for AR for short-term benefit.
 - Continuous grass pollen SLIT tablets or SLIT solution is recommended for AR for long-term benefit (Grade A).
 - HDM SLIT tablet can be recommended for AR for long-term benefit (Grade B for adults, C for children).
- Polysensitized patients who are poly-allergic for taxonomically related homologous allergens can be recommended to receive either a single allergen or a mixture of homologous allergens from that biological family that covers all the major allergens (Grade A).
- Patients who are poly-allergic for nonhomologous allergens may be recommended to start AIT with either the allergen responsible for most of their allergic rhinoconjunctivitis symptoms or separate treatment with the 2 clinically most important allergens (Grade C).
- In children aged 2-5 y of age, it is recommended that consideration should be given to likely benefits and risks associated with AIT for AR (Grade D).
- AIT can be recommended in otherwise healthy elderly patients with AR whose symptoms cannot be adequately controlled by pharmacotherapy (Grade A for SLIT, B for SCIT).
- If patients have not started AIT and are pregnant, it is recommended to wait until after pregnancy to initiate therapy (Grade D).
- It can be recommended that patients on SLIT are followed up every 3 mo to maximize adherence (Grade B).
- To achieve long-term efficacy, it is recommended that a minimum of 3 y of therapy is used (Grade A).
- Premedication with an antihistamine is recommended as it reduces the frequency and severity of local and systemic cutaneous reactions but does not eliminate the risk of other systemic adverse reactions including anaphylaxis (Grade A).
- It is recommended that patients should wait in the clinic for at least 30 minutes after a SCIT injection (Grade C).
- It is recommended that SCIT should be administered by competent staff, trained to diagnosed symptoms of early systemic reactions or anaphylaxis, with immediate access to resuscitation equipment and a doctor trained in managing anaphylaxis. (Grade C).
- It is recommended that patients should wait in clinic for at least 30 minutes after an initial SLIT dosage and staff and equipment should be available to manage any severe local or systemic reaction or anaphylaxis (Grade C).
- It is recommended that patients receiving SLIT should be informed about how to recognize and manage adverse reactions, particularly severe ones (Grade D).




FIGURE 3 Approach to using allergen immunotherapy (AIT) for allergic rhinoconjunctivitis. Schematic illustration of the approach to using AIT for AR starting with self-medication and management in primary care moving to assessment by a clinician trained in clinical allergy for consideration and initiation of AIT in suitable patients. Structure of healthcare systems differs between countries

TABLE 9 Implementation considerations: AIT for treatment of allergic rhinoconjunctivitis

Recommendation areas	Barriers to implementation	Facilitators to implementation	Audit criteria	Resource implications
SCIT or SLIT therapy	Lack of awareness of how to assess severity of AR Appreciation of SCIT and SLIT as treatment options Access to providers offering SCIT and/or SLIT at convenient locations and/or affordable cost Lack of knowledge about the relative efficacies and safety of different products	Development of integrated care pathways for AR incorporating primary and secondary care Increase in number of specialists able and willing to provide SCIT and/or SLIT Subsidized provision of SCIT and SLIT Document detailing and training about the efficacy and safety of individual products	Proportion of patients with moderate-to-severe seasonal AR who are offered and use SCIT or SLIT	The resource implications include professional time to develop and agree integrated care pathways The costs of training and upskilling allergist (specialist and subspecialists) to deliver SCIT and/or SLIT Training of primary care nurses and doctors to deliver immunotherapy as shared care agreements where appropriate Financial costs of subsidizing access to SCIT and SLIT
Selecting the appropriate AIT in patients with polysensitization +/- polyallergy	Lack of documentation for individual AIT products Effective identification of the key allergen(s) driving symptoms	Information to clinicians and patients about the better efficacy of single allergen or a mixture of well-documented homologous allergens Use of component-resolved diagnosis and provocation testing	Proportion of patients receiving either a single allergen or a mixture of well-documented homologous allergens Proportion of patients where additional measures are taken to identify the driving allergen(s)	Training for clinicians Availability of appropriate AIT products Access to component-resolved diagnostics and provocation testing
Using AIT in patients with controlled, co-existing asthma	Lack of education of clinicians and patients	Information to clinicians and patients about safety of AIT with co-existing asthma Control asthma before commencing AIT	Proportion of patients with co-existing asthma receiving AIT	Available AIT service
Consideration of AIT in pediatric patients with AR	Available AIT clinical service for children	Information about the place of AIT in managing AR in children for health purchases, primary care clinicians and patients	Proportion of pediatric patients with moderate-to-severe seasonal AR who use continuous SCIT	Availability of a clinical service for children able to deliver AIT for AR.
Consideration of AIT in otherwise healthy elderly patients with AR	Lack of access to AIT for AR in general or specific products	Information about the place of AIT in managing AR in the elderly for health purchases, primary care clinicians and patients	Proportion of elderly patients with moderate-to-severe seasonal AR who use AIT	Availability of a clinical service able to deliver AIT for AR
Adherence to AIT	Lack of patient education about AIT	Information for patients and use of simple reminders Three-monthly follow-up for SLIT patients Good physician-patient relationship and communication regarding side-effects and time course of treatments	Assessment of understanding of patients on AIT Assessment of adherence and use of reminders by patients on AIT	Resources to educate patients Investment in written communication and regular follow-up with access to advice regarding side-effects if necessary
Use of premedication with an antihistamine to reduce adverse effects	Lack of knowledge by clinicians and patients	Training of clinicians using AIT	Proportion of patients who receive premedication with antihistamine	Resources for training clinical staff Availability of medication

(Continues)

TABLE 9 (Continued)

Recommendation areas	Barriers to implementation	Facilitators to implementation	Audit criteria	Resource implications
Observation for at least 30 min after a SCIT injection or initial SLIT dosage by trained staff	Lack of understanding by clinicians of delayed effects Lack of trained staff and workforce time pressures	Training of clinicians using SCIT and SLIT Staff availability and rotas for administration and observations	Proportion of patients who wait 30 min after receiving SCIT or initial SLIT dosage Proportion of staff trained in management of severe adverse reactions	Resources for training clinical staff Time set aside for observation
Information for patients receiving SLIT about how to recognize and manage reactions and when therapy should be temporarily interrupted	Lack of understanding by patients receiving SLIT and clinicians administering	Training of patients and clinicians	Proportion of patients receiving SLIT trained in the self-management of severe adverse reactions	Resources for training patients and clinicians

Fauquert, E Hamelmann, P Hellings, L Jacobsen, EF Knol, SY Lin, P Maggina, R Mösges, H Oude Elberink, G Pajno, EA Pastorello, M Penagos, G Rotiroti, CB Schmidt-Weber, F Timmermans, O Tsilochristou, E-M Varga, J Wilkinson, A Williams and L Zhang as members of the Taskforce plus I Agache, E Angier, M Fernandez-Rivas, M Jutel, S Lau, R van Ree, D Ryan, and GJ Sturm as chairs of the other AIT Guidelines were all involved in conceptualizing the guidelines and critically reviewed guideline drafts. S Dhmi and S Arasi also provided methodological support to the Taskforce. F Timmermans was the patient group representative. All the authors satisfied the international authorship criteria (further details in Table S2). This guideline is part of the EAACI Guidelines on AIT, chaired by Antonella Muraro, and coordinated by Graham Roberts.

CONFLICT OF INTEREST

G. Roberts has a patent issued: "Use of sublingual immunotherapy to prevent the development of allergy in at risk infants"; and his university has received payments for the activities he has undertaken giving expert advice to ALK, and presenting at company symposia for ALK, Allergen Therapeutics, and Meda, and serving as a member of an Independent Data Monitoring Committee for Merck outside of this work. O. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL-Allergy Holding B.V./HAL-Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biotech Tools S.A., Laboratorios LETI/LETI Pharma, and Anergis S.A.; grants from Biomay, Nuvo, and Circassia; and personal fees from MEDA Pharma, Sanofi US Services, Mobile Chamber Experts (a GA²LEN Partner), Novartis Pharma and Pohl-Boskamp, outside this work. CA Akdis has nothing to disclose. IJ. Ansotegui reports personal fees from SANOFI, Bayer, Pfizer, FAES FARMA, MIT FARMA, HIKMA, Menarini, and Bial Aristegui, outside this work. S. Durham reports grants from Regeneron (USA), Biotech Tools, ALK (Denmark), Food Standards Agency (UK), and National Institute of Health Research (UK) and personal fees from Anergis (Switzerland), Circassia (UK), Biomay (Austria), Merck, Allergy Therapeutics (UK), ALK (Hørsholm, Denmark), med update GmbH (Germany), and Allergy Therapeutics, outside of this work. R. Gerth van Wijk reports personal fees from ALK-Abello, Circassia, and Allergopharma, during the conduct of this work. S. Halcken reports personal fees from ALK-Abello and from different companies, for example, Meda, Stallergenes, Allergopharma, and ALK-Abello, outside of this work. D. Larnas-Linnemann reports grants and personal fees from Astrazeneca, Boehringer-Ingelheim, MEDA, Novartis, grants and personal fees from Sanofi, UCB, GSK, Pfizer, MSD, grants from Chiesi, TEVA, personal fees from Grunenthal, Amstron, Stallergenes, ALK-Abelló, personal fees from DBV, outside the submitted work; and Chair immunotherapy committee CMICA, Member immunotherapy committee or interest group EAACI, WAO, SLAAI, Board of Directors and Program Chair CMICA 2018-2019. R. Pawankar has nothing to disclose. C. Pitsios has nothing to disclose. A. Sheikh reports grants from the EAACI during the conduct of this work. M. Worm reports grants from Allergopharma, Novartis, Stallergenes, Medic Pharma,

TABLE 10 Gaps in the evidence for allergen immunotherapy (AIT) for allergic rhinoconjunctivitis

Gaps	Plan to address	Priority
Lack of biomarkers to predict and quantify the effectiveness of AIT	Prospective observational studies to validate potential predictive biomarkers	High
Agreement about the clinically meaningful effect size of AIT treatment (active vs placebo treated patients)	Consensus discussion	High
Low risk of bias randomized controlled data for children and adolescents	More prospective controlled trials using standardized products	High
Evidence for long-term clinical effectiveness after treatment cessation	More prospective controlled trials with follow-up post-treatment cessation in adults and children	High
Standardization of grading of adverse effects of AIT	Future clinical trials should use the WAO local and systemic reaction grading system	High
Approaches to improve adherence with AIT	Working with patients to develop novel approaches that can be tested in prospective controlled trials and real-life settings	High
Randomized cost-effectiveness and cost-utility studies adjusted to socioeconomic differences within and between countries	Additional multinational studies with a health economics focus	High
For some AIT products, there is little or no evidence for clinical effectiveness	Dose ranging studies to optimize dose for efficacy and safety; prospective controlled trials; use of patient reported outcomes; use of products with proven effectiveness	High
Approaches to minimize adverse effects	More prospective observation and controlled trials. A subanalysis of different phenotypes populations in current RCTs and real-life settings	Moderate
Effectiveness of mixtures of homologous allergens from the same, related or different biological families	More prospective controlled trials using the commonest allergens	Moderate
Good evidence base for contraindications to AIT	Registries recording patient details, AIT, outcome and adverse effects	Moderate
Value of provocation tests in identifying the most appropriate allergen to use in AIT	Prospective controlled studies to assess benefit of provocation testing	Moderate
Management of AIT in patients who become pregnant on therapy	More prospective observational studies	Low
Lack of standardized AIT preparations for orphan allergens	Multicentre studies	Low

BOX 6 Key messages for primary care

- Diagnosis of AR is by history
- Where severe, treat with nonsedating, long-acting antihistamine and topical nasal corticosteroid (with appropriate nasal spray training) and/or topical ocular cromoglycate or antihistamine.
- Check for any co-existing asthma; this should be properly controlled when using AIT.
- AIT is effective for AR driven by pollens, house dust mite, and animal dander.
- AIT is indicated for AR with moderate-to-severe symptoms that are not controlled by pharmacotherapy or avoidance strategies (where appropriate).
- AIT may be given by subcutaneous (SCIT) or sublingual route (SLIT) as either SLIT tablets or SLIT drops.
- AIT therapy needs to be continued for at least 3 y for postcessation effectiveness.
- Local adverse effects, which are mild in severity and self-limited without the use of rescue medication, are common with SLIT when starting therapy.
- More severe systemic allergic adverse events are infrequently seen and more commonly with SCIT than SLIT.
- SCIT injections and the initial SLIT dose should be given by healthcare personal who are trained in AIT and the management of any adverse events.
- At least a 30-minute observation period is required for all SCIT injections and the initial dose of SLIT.

and ALK-Abello. S. Arasi reports payment from Evidence-Based Health Care Ltd during the conduct of this work. M. Calderon has received honorarium in advisory boards for ALK and Hal-Allergy and served as a speaker for ALK, Merck, and Stallergenes Greer. C. Cingi has nothing to disclose. S. Dhimi reports grants from EAACI to carry out the review, during the conduct of this work. JL Fauquet has nothing to disclose. E. Hamelmann has served on scientific advisory boards and received honorarium for lectures on scientific meetings for ALK, AllergoPharma, Bencard, HAL, Leti, Stallergenes. P. Hellings has nothing to disclose. L. Jacobsen reports personal fees from EAMG, outside this work. E.F. Knol has nothing to disclose. S.Y. Lin has nothing to disclose. P. Maggina has nothing to disclose. R. Mosges reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Friulchem, Hexal, Servier, Klosterfrau, Bayer, FAES, GSK, MSD, Johnson & Johnson, Meda, Stada, UCB, and Nuvo; grants from ASIT biotech, Leti, Optima, bitop AG, Hulka, and Ursapharm; grants and personal fees from Bencard and Stallergenes; grants, personal fees, and nonfinancial support from Lofarma; nonfinancial support from Roxall, Atmos, Bionorica, Otonomy, and Ferrero; and personal fees and nonfinancial support from Novartis, outside this work. H. Oude Elberlink reports grants from ALK-Abello during the conduct

of this work. G.B. Pajno reports grants from Stallergenes during the conduct of this work. E.A. Pastorello has nothing to disclose. M. Penagos reports personal fees from Stallergenes and ALK, outside this work. G. Rotiroti reports personal fees from ALK-Abello, outside this work. C. Schmidt-Weber reports grants from Allergopharma and Leti and honorarium from PLS-Design, Allergopharma, and Leti; is a member of scientific advisory board for Leti; holds shares in PLS-Design; and hopes to develop a patent. F. Timmermans has nothing to disclose. O. Tsilochristou has nothing to disclose. E-M Varga reports lecture fees from ALK-Abello, Stallergenes Greer, Allergopharma, Bencard, MEDA, and Nutricia outside the submitted work. J. Wilkinson has nothing to disclose. A. Williams reports other grants from ALK-Abello (UK) and Diagenics Ltd (UK), outside this work; and travel expenses for education meetings from the EAACI and BSACI. L. Zhang has nothing to disclose. I. Agache has nothing to disclose. E. Angier reports previous advisory board membership for Stallergenes, Meda, and Schering Plough plus a sponsored lecture by Meda and attendance at a ALK SOSA meeting. M. Fernandez-Rivas reports personal fees from ALK, Merck, and GSK. M. Jutel reports personal fees from Allergopharma, Anergis, Stallergenes, ALK, LETI outside the submitted work. S. Lau reports a grant from Allergopharma plus personal fees for data monitoring committee activities for Merck. R. van Ree reports personal fees from HAL-Allergy BV and Citeq BV outside of the submitted work. D. Ryan reports personal fees from Stallergenes, Thermo Fisher, MEDA outside of the submitted work. G. Sturm reports grants and personal fees from ALK-Abello, Novartis, Stallergenes, Bencard Allergy, and Leti outside of the submitted work. A. Muraro reports speaker's honoraria for Novartis, Meda, Nestle, Stallergenes, ALK outside the submitted work.

ORCID

G. Roberts  <http://orcid.org/0000-0003-2252-1248>

O. Pfaar  <http://orcid.org/0000-0003-4374-9639>

REFERENCES

1. Eifan WO, Durham SR. Pathogenesis of rhinitis. *Clin Exp Allergy*. 2016;46:1139-1151.
2. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. *Lancet*. 2011;378:2112-2122.
3. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. *J Allergy Clin Immunol*. 2010;126:778.
4. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the pediatric allergies in America survey. *J Allergy Clin Immunol*. 2009;124:S43-S70.
5. Ait-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. *Allergy*. 2009;64:123-148.
6. Walker S, Khan W, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. *J Allergy Clin Immunol*. 2007;120:381-387.

7. Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. *Allergy*. 2013;68:1102-1116.
8. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma ARIA 2008 update in collaboration with the World Health Organization, GA2LEN and Aller Gen. *Allergy*. 2008;63:8-160.
9. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. *New Engl J Med*. 2003;349:237-246.
10. Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database of Systematic Reviews. 2010, Issue 7. Art. No.: CD001563. <https://doi.org/10.1002/14651858.CD001563.pub3>.
11. Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). *Allergo J Int*. 2014;23:282-319.
12. Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. *J Allergy Clin Immunol*. 2015;136:556-568.
13. Jutel M, Agache I, Bonini S, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. *J Allergy Clin Immunol*. 2016;137:358-368.
14. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. *Allergy*. 2017;72:1597-1631.
15. Rondón C, Canto G, Blanca M. Local allergic rhinitis: a new entity, characterization and further studies. *Curr Opin Allergy Clin Immunol*. 2010;10:1-7.
16. Rondon C, Campo P, Herrera R, et al. Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis. *J Allergy Clin Immunol*. 2011;128:1192-1197.
17. Agree Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care*. 2003;12:18-23.
18. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *Can Med Assoc J*. 2010;182:E839-E842.
19. Dhami S, Nurmatov U, Roberts G, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review Clinical and Translational. *Allergy*. 2016;6:12.
20. Oxford Centre for Evidence-based Medicine. Levels of evidence and grades of recommendation. 2013. <http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/> (last accessed 27 July 2017).
21. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases A WHO position paper. *J Allergy Clin Immunol*. 1998;102:558-562.
22. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol*. 2010;126:466-476.
23. Halcken S, Larenas-Linnemann D, Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: prevention of allergy. *Pediatr Allergy Immunol*. 2017;28:728-745.
24. Bachert C, Larche M, Bonini S, et al. Allergen immunotherapy on the way to product-based evaluation – a WAO statement. *World Allergy Organ J*. 2015;8:29.
25. Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. *Pediatr Allergy Immunol*. 2017;28:18-29.
26. Campo P, Rondón C, Gould HJ, Barrionuevo E, Gevaert P, Blanca M. Local IgE in non-allergic rhinitis. *Clin Exp Allergy*. 2015;45:872-881.
27. Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. *Allergy*. 2015;70:897-909.
28. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. *J Allergy Clin Immunol*. 2011;127:S1-S55.
29. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: systemic reactions during the rush protocol in patients suffering from asthma. *J Allergy Clin Immunol*. 1989;83:797-802.
30. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. *Ann Allergy Asthma Immunol*. 2001;87:47-55.
31. Bernstein DI, Wanner M, Borish L, Liss GM. Immunotherapy Committee AOA, and immunology: twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. *J Allergy Clin Immunol*. 2004;113:1129-1136.
32. CSM. Update: desensitising vaccines. *Br Med J*. 1986;293:948.
33. Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. Cochrane Database of Systematic Reviews. 2015, Issue 8. Art. No.: CD011293. <https://doi.org/10.1002/14651858.CD011293.pub2>.
34. Calderon MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. *Allergy*. 2012;67:302-311.
35. Cabrera GE, Citera G, Gutiérrez M, Scopelitis E, Espinoza LR. Digital vasculitis following allergic desensitization treatment. *J Rheumatol*. 1993;20:1970-1972.
36. Sánchez-Morillas L, Reaño Martos M, Iglesias Cadarso A, Pérez Pimiento A, Rodríguez Mosquera M, Domínguez Lázaro AR. Vasculitis during immunotherapy treatment in a patient with allergy to *Cupressus arizonica*. *Allergol Immunopathol*. 2005;33:333-334.
37. Fiorillo A, Fonacier L, Diola C. Safety of allergenic immunotherapy in systemic lupus erythematosus. *J Allergy Clin Immunol*. 2006;117(2 Suppl):S264.
38. Wöhr S, Kinaciyan T, Jalili A, Stingl G, Moritz KB. Malignancy and specific allergen immunotherapy: the results of a Case Series. *Int Arch Allergy Immunol*. 2011;156:313-319.
39. Larenas-Linnemann DES, Hauswirth DW, Calabria CW, Sher LD, Rank MA. American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. *Allergy Asthma Proc*. 2016;37:e112-e122.
40. Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. *J Allergy Clin Immunol*. 1978;61:268-272.
41. Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. *JAMA*. 2016;315:1715-1725.
42. Hiatt WR, Wolfel EE, Stoll S, et al. beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. *Clin Pharmacol Ther*. 1985;37:2-6.
43. Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. *Allergy*. 2017;72:1825-1848.

44. Cleaveland CR, Rangno RE, Shand DG. A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol. *Arch Intern Med.* 1972;130:47-52.
45. Lang DM. Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. *Drug Saf.* 1995;12:299-304.
46. Linneberg A, Jacobsen RK, Jespersen L, Abildstrom SJ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. *J Allergy Clin Immunol.* 2012;129:413-419.
47. Bonertz A, Roberts G, Hoefnagel M, et al. Challenges in the implementation of EAACI Guidelines on Allergen Immunotherapy: a global perspective on the regulation of allergen products. *Allergy* 2018;73:64-76.
48. Ryan D, Gerth van Wijk R, Angier E, et al. Challenges in the implementation of the EAACI AIT guidelines: a situational analysis of current provision of allergen immunotherapy. *Allergy* 2018;73:827-836.
49. Tworek D, Bochenska-Marciniak M, Kuprys-Lipinska I, Kupczyk M, Kuna P. Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis. *Am J Rhinol Allergy.* 2013;27:304-308.
50. Passalacqua G, Pasquali M, Ariano R, et al. Randomized double blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. *Allergy.* 2006;61:849-854.
51. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2016;138:1631-1638.
52. Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. *J Allergy Clin Immunol.* 2016;137:444-451.
53. Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. *J Allergy Clin Immunol.* 2014;133:1608-1614.
54. Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. *Ann Allergy Asthma Immunol.* 2015;114:134-140.
55. Okubo K, Masuyama K, Imai T, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. *J Allergy Clin Immunol.* 2017;139:1840-1848.
56. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. *J Allergy Clin Immunol.* 2007;120:1338-1345.
57. Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. *Allergy.* 2006;61:1177-1183.
58. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol.* 2006;117:319-325.
59. Demoly P, Calderon MA. Dosing and efficacy in specific immunotherapy. *Allergy.* 2011;66(Suppl. 95):38-40.
60. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. *J Allergy Clin Immunol.* 2001;107:87-93.
61. Charpin D, Gouitaa M, Dron-Gonzalvez M, et al. Immunotherapy with an aluminum hydroxide-adsorbed *Juniperus ashei* foreign pollen extract in seasonal indigenous cypress pollen rhinoconjunctivitis. A double-blind, placebo-controlled study. *Int Arch Allergy Immunol.* 2007;143:83-91.
62. Ferrer M, Burches E, Peláez A, et al. Double-blind, placebo-controlled study of immunotherapy with *Parietaria judaica*: clinical efficacy and tolerance. *J Investig Allergol Clin Immunol.* 2005;15:283-292.
63. Jacobsen L, Niggemann B, Dreborg S, et al.; The PAT Investigator Group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy.* 2007;62:943-948.
64. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. *Allergy.* 1996;51:489-500.
65. Scadding GW, Calderon MA, Shamji MH, et al.; Immune Tolerance Network GRASS Study Team. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. *JAMA.* 2017;14:615-625.
66. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. *Clin Exp Allergy.* 2003;33:1076-1082.
67. Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E. Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up. *Makedon Akad Na Nauk Umet Oddelenie Za Bioloski Meditsinski Nauki Pril.* 2005;26:113-129.
68. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. *Clin Exp Allergy.* 1988;18:501-508.
69. Balda BR, Wolf H, Baumgarten C, et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven pre-seasonal injections of molecular standardized allergens. *Allergy.* 1998;53:740-748.
70. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. *Allergy.* 2002;57:297-305.
71. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. *BMJ.* 1991;302:265-269.
72. Zenner HP, Baumgarten C, Rasp G, et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. *J Allergy Clin Immunol.* 1997;100:23-29.
73. Weyer A, Donat N, L'Heritier C, et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. *Allergy.* 1981;36:309-317.
74. Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. *J Allergy Clin Immunol.* 1990;80:591-598.
75. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. *J Allergy Clin Immunol.* 2005;116:608-613.
76. Brunet C, Bédard PM, Lavole A, Jobin M, Hébert J. Allergic rhinitis to ragweed pollen: I. Reassessment of the effects of immunotherapy on cellular and humoral responses. *J Allergy Clinical Immunol.* 1992;89:76-86.
77. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A; for the Study Group. Efficacy and safety of preseasonal-specific

- immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. *Allergy*. 2005;60:801-807.
78. Klimek L, Uhlig J, Mosges R, Rettig K, Pfaar O. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. *Allergy*. 2014;69:1629-1638.
 79. Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of *Parietaria judaica* in patients with *Parietaria* hay fever. *Allergy*. 1994;49:13-21.
 80. Tabar AI, Lizaso MT, García BE, et al. Double-blind, placebo-controlled study of *Alternaria* immunotherapy: clinical efficacy and safety. *Pediatr Allergy Immunol*. 2008;19:67-75.
 81. Ceuppens JL, Bullens D, Kleinjans H, van der Werf J, Purethal Birch Efficacy Study Group. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects. *Clin Exp Allergy*. 2009;39:1903-1909.
 82. Riechelmann H, Schmutzhard J, van der Werf JF, Distler A, Kleinjans HA. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. *Am J Rhinol Allergy*. 2010;24:104-109.
 83. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med*. 1999;341:468-475.
 84. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. *J Allergy Clin Immunol*. 2011;127:509-516.
 85. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. *Allergy*. 2006;61:185-190.
 86. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 2006;118:434-440.
 87. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 2006;117:802-809.
 88. Pajno GB, Caminiti L, Crisafulli G, et al. Adherence to sublingual immunotherapy in preschool children. *Pediatr Allergy Immunol*. 2012;23:688-689.
 89. Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. *Clin Transl Allergy*. 2014;11:7.
 90. Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. *Allergy*. 2000;55:1142-1147.
 91. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to *Parietaria* pollen treated with inhaled fluticasone propionate. *Clin Exp Allergy*. 2003;33:1641-1647.
 92. Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-seasonal and continuous grass sublingual immunotherapy in children. *Allergy*. 2012;67:312-320.
 93. Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. *J Allergy Clin Immunol*. 2013;131:1342-1349.
 94. Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. *Clinical Translational Allergy*. 2015;5:12.
 95. Drachenberg K, Heinzkill M, Urban E. Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid-A - Results from a multicentre, placebo-controlled, randomised, double-blind study. [Kurzzeit-Immuntherapie mit Baumpollen-Allergoiden und dem Adjuvans Monophosphoryl Lipid-A]. *Allergologie*. 2002 Jahrgang, Nr. 9;S. 466-474.
 96. Palma-Carlos AG, Santos AS, Branco-Ferreira M, et al. Clinical efficacy and safety of pre-seasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. *Allergol Immunopathol (Madr)*. 2006;34:194-198.
 97. Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. *Pediatr Allergy Immunol*. 2010;21:970-976.
 98. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. *J Allergy Clin Immunol*. 2009;123:167-173.
 99. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. *J Allergy Clin Immunol*. 2011;127:64-71.
 100. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. *J Allergy Clin Immunol*. 2009;124:150-156.
 101. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of *Cupressus arizonica*. A double blind study. *Allergol Immunopathol (Madr)*. 2001;29:238-244.
 102. Panzner P, Petras M, Sykora T, Lesna I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. *Respir Med*. 2008;102:1296-1304.
 103. Bufe A, Ziegler-Kirbach E, Stoeckmann E, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. *Allergy*. 2004;59:498-504.
 104. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. *Allergol Immunopathol*. 1995;23:224-230.
 105. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. *Ann Allergy Asthma Immunol*. 2004;93:425-430.
 106. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. *Allergol Immunopathol (Madr)*. 1990;18:277-284.
 107. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. *Allergy*. 2000;55:369-375.
 108. Didier A, Malling HJ, Worm M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. *Clin Exp Allergy*. 2013;43:568-577.
 109. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. *J Allergy Clin Immunol*. 2012;129:717-725.
 110. Valovirta E, Berstad AK, de Blic J, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass Pollen-Induced allergic rhinoconjunctivitis. *Clin Ther*. 2011;33:1537-1546.
 111. Valovirta E, Petersen TH, Piotrowska T, et al., GAP Investigators. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. *J Allergy Clin Immunol*. 2018;141:529-538.
 112. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. *Curr Opin Allergy Clin Immunol*. 2012;12:648-657.

113. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. *Allergy*. 2001;56:498-505.
114. DuBuske L, Frew A, Horak F, Keith P, Corrigan C, Aberer W. Ultra-short-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. *Allergy Asthma Proc*. 2011;32:239-247.
115. Creticos PS, Schroeder JT, Hamilton RG, et al.; Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. *N Engl J Med*. 2006;355:1445-1455.
116. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. *Omalizumab Rhinitis Study Group*. *Allergy*. 2004;59:973-979.
117. Casale TB, Busse WW, Kline JN, et al.; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. *J Allergy Clin Immunol*. 2006;117:134-140.
118. Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. *J Allergy Clin Immunol*. 2014;133:937.
119. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 2008;122:951-960.
120. Zieglmayer P, Focke-Tejkl M, Schmutz R, et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. *EBioMedicine*. 2016;11:43-57.
121. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. *J Allergy Clin Immunol*. 2013;131:103-109.
122. <http://www.circassia.com/media/press-releases/circassia-announce-s-top-line-results-from-cat-allergy-phase-iii-study/>. (accessed 31 July 2017)
123. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. *J Allergy Clin Immunol*. 2010;125:569-574.
124. Spertini F, DellaCorte G, Kettner A, et al. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. *J Allergy Clin Immunol*. 2016;138:162-168.
125. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. *J Allergy Clin Immunol*. 2012;129:128-135.
126. Slovick A, Douiri A, Muir R, et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. *J Allergy Clin Immunol*. 2017;139:1830-1839.
127. Senti G, Cramer R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. *J Allergy Clin Immunol*. 2012;129:1290-1296.
128. Patterson AM, Bonny AE, Shiels WE, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. *Ann Allergy Asthma Immunol*. 2016;116:168-170.
129. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? *J Allergy Clin Immunol*. 2013;132:1248-1252.
130. Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. *Allergol Immunopathol (Madr)*. 2003;31:270-277.
131. Patel P, Holdich T, von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. *J Allergy Clin Immunol*. 2014;133:121-129.
132. European Medicines Agency. *Guideline on Allergen Products: Production and Quality Issues*. London: Published by European Medicines Agency; 2008. EMEA/CHMP/BWP/304831/2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003333.pdf (accessed 13th August 2017)
133. Coop CA. Immunotherapy for mold allergy. *Clin Rev Allergy Immunol*. 2014;47:289-298.
134. Twaroch TE, Curin M, Valenta R, Swoboda I. Mold allergens in respiratory allergy: from structure to therapy. *Allergy Asthma Immunol Res*. 2015;7:205-220.
135. Lizaso MT, Martínez A, Asturias JA, et al. Biological standardization and maximum tolerated dose estimation of an *Alternaria alternata* allergenic extract. *J Invest Allergol Clin Immunol*. 2006;16:94-103.
136. Slater JE, Zoch A, Newman-Gerhardt S, Khurana T. Comparison of total protein profile of *alternaria* extract obtained from various U.S. Allergenic extract manufacturers. *J Allergy Clin Immunol*. 2014;133:AB100.
137. Demoly P, Passalacqua G, Pfaar O, Sastre J, Wahn U. Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. *Allergy Asthma Clin Immunol*. 2016;12:2.
138. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol*. 2014;134:568-575.
139. Bahceciler NN, İşik UI, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. *Pediatr Pulmonol*. 2001;32:49-55.
140. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. *Paediatr Allergy Immunol*. 1997;8:21-27.
141. Larenas-Linnemann D, et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. *Ann Allergy Asthma Immunol*. 2011;107:448-458.
142. Pfaar O, Biedermann T, Klimek L, Sager A, Robinson DS. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients. *Allergy*. 2013;68:1306-1313.
143. Swamy RS, Reshamwala N, Hunter T, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. *J Allergy Clin Immunol*. 2012;130:215-224.
144. Marcucci F, Sensi L, Frati F, et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. *Allergy*. 2003;58:657-662.
145. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. *Allergy*. 2009;64:1394-1401.
146. de Bot CMA, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. *Pediatr Allergy Immunol*. 2012;23:151-159.
147. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. *Lancet*. 1998;351:629632.
148. Miguères M, Dávila I, Frati F, et al. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. *Clin Transl Allergy*. 2014;4:16.

149. Nelson H, Blaiss M, Nolte H, Würtz SØ, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. *Allergy*. 2013;68:252-255.
150. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. *N Engl J Med*. 1997;336:324-332.
151. Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. *J Allergy Clin Immunol*. 2009;123:763-769.
152. Shao J, Cui YX, Zheng YF, et al. Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. *Am J Rhinol Allergy*. 2014;28:131-139.
153. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. *Ann Allergy Asthma Immunol*. 2005;95:254-258.
154. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. *Allergy*. 2005;60:133-134.
155. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. *J Allergy Clin Immunol*. 2006;117:263-268.
156. Wahn U, Tabar A, Kuna P, et al.; SLIT Study Group. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. *J Allergy Clin Immunol*. 2009;123:160-166.
157. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. *Allergy*. 2006;61:198-201.
158. Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C, Kalayci O. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. *Pediatr Allergy Immunol*. 2006;17:396-407.
159. Bozek A, Kolodziejczyk K, Warkocka-Szolysek B, Jarzab J. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. *Am J Rhinol Allergy*. 2014;28:423-427.
160. Bozek A, Kolodziejczyk K, Krajewska-Wojtys A, Jarzab J. Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass. *Ann Allergy Asthma Immunol*. 2016;116:156-161.
161. Shaikh WA, Shaikh SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. *Allergy*. 2012;67:741-743.
162. Oykman P, Kim HL, Ellis AK. Allergen immunotherapy in pregnancy. *Allergy Asthma Clin Immunol*. 2015;11:31.
163. Incorvaia C, Masieri S, Berto P, Scurati S, Frati F. Specific immunotherapy by the sublingual route for respiratory allergy. *Allergy Asthma Clin Immunol*. 2010;6:29.
164. Scurati S, Frati F, Passalacqua G, Puccinelli P, Hilaire C, Incorvaia C; Italian Study Group on SLIT Compliance. Adherence issues related to sublingual immunotherapy as perceived by allergists. *Patient Prefer Adherence*. 2010;4:141-145.
165. Egert-Schmidt AM, Kolbe JM, Mussler S, Thum-Oltmer S. Patients' compliance with different administration routes for allergen immunotherapy in Germany. *Patient Prefer Adherence*. 2014;8:1475-1481.
166. Kiel MA, Röder E, van Wijk RG, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. *J Allergy Clin Immunol*. 2013;132:353-360.
167. Vaswani R, Garg A, Parikh L, Vaswani S. Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause. *Ann Allergy Asthma Immunol*. 2015;115:241-243.
168. Leader BA, Rotella M, Stillman L, DelGaudio JM, Patel ZM, Wise SK. Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy. *Int Forum Allergy Rhinol*. 2016;6:460-464.
169. Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. *Allergy*. 2013;68:1193-1195.
170. Makatsori M, Scadding GW, Lombardo C, et al. Dropouts in sublingual allergen immunotherapy trials – a systematic review. *Allergy*. 2014;69:571-580.
171. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. *Allergy*. 2010;65:668-669.
172. Patel P, Holdich T, von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. *J Allergy Clin Immunol*. 2014;133:121-129.
173. Rienzo VD, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. *Clin Exp Allergy*. 2005;35:560-564.
174. Rodriguez-Santos O. Sublingual immunotherapy in allergic rhinitis and asthma in 2-5-year-old children sensitized to mites. *Rev Allerg Mex*. 2008;55:71-75.
175. Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. *Clin Exp Allergy*. 2012;43:242-248.
176. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. *J Allergy Clin Immunol*. 2010;125:131-138.
177. Lin Z, Liu Q, Li T, Chen D, Chen D, Xu R. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. *Int Forum Allergy Rhinol*. 2016;6:82-87.
178. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. *J Allergy Clin Immunol*. 1997;100:293-300.
179. Arroabarren E, Tabar AI, Echechipia S, Cambra K, García BE, Alvarez-Puebla MJ. Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy. *Pediatr Allergy Immunol*. 2015;26:34-41.
180. Cox L, Calderon M, Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. *Immunotherapy*. 2012;4:601-616.
181. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. *Drug Saf*. 2000;23:323-332.
182. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. *Ann Allergy Asthma Immunol*. 2011;107:426-431.
183. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008–2013). *Ann Allergy Asthma Immunol*. 2016;116:354-359.
184. Calderon MA, Vidal C, Rodriguez del Rio P, et al. on behalf of the EASSI Doctors' Group. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment. *Allergy*. 2017;72:462-472.
185. Rodríguez del Río P, Vidal C, Just J, et al. The European survey on adverse systemic reactions in allergen immunotherapy (EASSI): a paediatric assessment. *Pediatr Allergy Immunol*. 2017;28:60-70.
186. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. *Ann Allergy Asthma Immunol*. 2004;92:225-227.

187. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. *J Allergy Clin Immunol.* 1996;97:1207-1213.
188. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. *Allergy.* 2000;55:484-488.
189. Brehler R, Klimek L, Pfaar O, Hauswald B, Worm M, Bieber T. Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. *Allergy Asthma.* 2010;31:3138.
190. Cardona R, Lopez E, Beltran J, Sanchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultrarush build-up. A retrospective study. *Allergol Immunopathol (Madr).* 2014;42:90-95.
191. Casanovas M, Martin R, Jimenez C, Caballero R, Fernandez-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. *Int Arch Allergy Immunol.* 2006;139:153-158.
192. Casanovas M, Martin R, Jimenez C, Caballero R, Fernandez-Caldas E. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. *Clin Exp Allergy.* 2007;37:434-440.
193. Vogelbruch M, Nuss B, Körner M, Kapp A, Kiehl P, Bohm W. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. *Allergy.* 2000;55:883-887.
194. Netterlid E, Hindsén M, Björk J, et al. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy. *Contact Dermatitis.* 2009;60:41-49.
195. Frost L, Johansen P, Pedersen S, Veien N, Ostergaard PA, Nielsen MH. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. *Allergy.* 1985;40:368-372.
196. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database Syst Rev.* 2010;12:CD002893.
197. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. *World Allergy Organ J.* 2014;7:6.
198. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. *J Allergy Clin Immunol.* 2006;117:1021-1035.
199. Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. *J Allergy Clin Immunol.* 2013;132:93-98.
200. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. *J Allergy Clin Immunol.* 2006;117:169-175.
201. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. *Health Technol Assess.* 2013;17:1-322.
202. Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. *Allergy Asthma Proc.* 2006;27:159-163.
203. Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. *Allerg Immunol (Paris).* 2005;37:303-308.
204. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. *J Allergy Clin Immunol.* 2008;121:227-232.
205. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. *Ann Allergy Asthma Immunol.* 2010;104:79-85.
206. Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. *J Allergy Clin Immunol.* 2013;131:1084-1091.
207. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. *N Engl J Med.* 1996;334:501-506.
208. Berto P, Frati F, Incorvaia C, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. *Curr Med Res Opin.* 2008;24:261-266.
209. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. *Pharmacoeconomics.* 2000;17:37-52.
210. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. *Allergol Immunopathol (Madr).* 2005;33:296-302.
211. Berto P, Passalacqua G, Crimi N, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. *Ann Allergy Asthma Immunol.* 2006;97:615-621.
212. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis—a Northern European perspective. *Clin Exp Allergy.* 2007;37:772-779.
213. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. *Allergy.* 2008;63:1624-1629.
214. Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U. Economic evaluation of a tablet-based vaccination against hay fever in Denmark. *Ugeskr Laeger.* 2008;14:138-142.
215. Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. *Curr Med Res Opin.* 2007;23:1113-1120.
216. Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax) in children. *Clin Outcomes Res.* 2014;6:187-196.
217. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. *J Med Econ.* 2012;15:906-917.
218. Verheggen B, Westerhout K, Schreder C, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. *Clin Transl Allergy.* 2015;5:1.
219. Reinhold T, Brüggengjürgen B. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment. *Allergo J Int.* 2017;26:7-15.
220. Asaria M, Dhami S, van Ree R, et al. Health economic analysis of allergen immunotherapy (AIT) for the management of allergic rhinitis, asthma, Food allergy and venom allergy: a systematic overview. *Allergy* 2018;73:269-283.
221. Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. *J Allergy Clin Immunol.* 2015;3:256-266.
222. Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. *Allergy.* 2017;72:1156-1173.

223. Stelmach I, Sobocińska A, Majak P, Smejda K, Jerzyńska J, Stelmach W. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. *Ann Allergy Asthma Immunol*. 2012;109:274-278.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. *Allergy*. 2018;73:765-798. <https://doi.org/10.1111/all.13317>